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ABSTRACT 
A cress-sectional hospital base study was conducted to analyze fetomaternal 
outcome in eclampsia, clinical characteristics that predispose as risk factors, 
changes in serum magnesium level and its influence on maternal outcome. Study 
conducted from 1
st
 March 2010 to 30
th
 June 2011 in the department of Obstetrics 
and Gynecology, Coimbatore Medical College Hospital, Coimbatore.  
In our study there were total of 104 eclamptic patients with an incidence of 
1.23%. Only 65.38% were booked patients and with regular antenatal checkups. 
Primigravida constituted 76%. Maximum incidence of eclampsia was in the age 
group between 21 and 25 years (58%). Antepartum eclampsia constituted 81%. 
Mean blood pressure on admission was 156 ± 15 / 103 ± 12 mm Hg. Headache was 
the commonest imminent symptom. 57% had vaginal delivery. Serum magnesium 
level was significantly low (1.74 ± 0.28 mg/dl ; p value < 0.05) in eclamptic 
patients. Maternal complications included PPH, HELLP, renal failure, abruptio 
placenta, pulmonary edema, aspiration and intra cerebral hemorrhage in decreasing 
order of frequency. There were 4 maternal deaths with case fatality ratio of 3.84%, 
contributing 10.5% of total maternal deaths. Half of the deaths were due to 
HELLP-DIC. Age >25 years, multipara, unbooked patients, seizures ≥ 5 episodes, 
systolic BP ≥ 160 mm Hg were significantly associated with maternal 
complications. Platelet less than 1 lakh and serum magnesium level less than 1.6 
mg/dl were associated significantly with adverse maternal outcome. Perinatal 
complications included small for gestational age, preterm, jaundice, seizures, 
respiratory distress, sepsis. There were 30 perinatal deaths contributing to 6.96% of 
total perinatal mortality. Perinatal mortality rate was 3.56/1000 live births. 
Multiparity, gestational age ≤ 32 weeks, seizures >5 episodes were significantly 
associated with perinatal mortality. 
Key words: Eclampsia, fetomaternal outcome, serum magnesium. 
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INTRODUCTION 
Eclampsia has been a recognized pathological entity since the time 
of Hippocrates and ancient Greek.
1
 It is derived from the Greek word 
meaning “flash out”, in the sense of sudden event and dates back to 
seventeenth century. Eclampsia is perceived as the end of linear spectrum 
that stretches from the normal pregnancy through mild gestational 
hypertension, pre-eclampsia finally eclampsia. 
It is an enigmatic disease and unique to pregnancy.A number of 
social, genetic, medical and obstetric conditions predispose to an increase 
risk of pre-eclampsia and eclampsia. It is the multisystem disorder. The 
exact etiology of pre-eclampsia is unknown. Several theories have been 
proposed over the years, most of which have not withstood the test of 
time. Some of these failed to stand up to further investigation, while 
others yielded conflicting results in different studies, and none could 
explain all the changes in this condition. As Boyd stated pre-eclampsia 
remains “die krankheit der theorian” – the disease of theories. 
Worldwide it accounts for 50,000 maternal deaths annually.
2 
It is 
said that pre-eclampsia and eclampsia contribute to death of a women 
every 3 minutes worldwide.
3
20 times more common in developing 
countries.Incidence of eclampsia in India is approximately 220 per 
10,000 deliveries, contributing about 8% of maternal mortality
4
. It ranks 
second only to anemia in developing countries. 
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Pre-eclampsia is not preventable but eclampsia is preventable.In 
spite of the global and regional interventions and initiatives from 
government, its outcome in terms of maternal and perinatal mortality 
continues to be worse. Eclampsia is preceded by alarming symptoms and 
signs of pregnancy induced hypertension.The institution of vigilant 
antenatal care to detect risk factors and prompt treatment of cases of pre-
eclampsia will ameliorate the disease burden. 
Incidence, morbidities and mortalities of eclampsia remain 
unacceptably high in developing countries. This indicates the need for 
continued in depth studies into its characteristics and pattern. This study 
was undertaken to determine the incidence of eclampsia, identify the 
predisposing socio-demographic factors, demonstrate clinical profiles, 
changes in serum magnesium levels and analyze modes of management 
and resulting maternal and fetal outcome at Coimbatore Medical College 
Hospital. 
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AIM OF THE STUDY 
 
1. To record the clinical profile of patients with eclampsia and to assess 
the incidence of eclampsia. 
2. To study the various maternal and fetal outcome by means of 
morbidity and mortality in eclampsia. 
3. To analyze the clinical characteristics that predisposes as risk factor 
for eclampsia and fetomaternal outcome. 
4. To analyze the changes in platelet count, serum magnesium level 
and their influence on maternal outcome. 
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REVIEW OF LITERATURE 
Hypertensive disorders complicate 5 to 10 % of all pregnancies and 
together they form the deadly triad along with hemorrhage and infection, 
contribute greatly to maternal morbidity and mortality rates. In developed 
countries, 16% of maternal mortality was due to hypertensive disorders
5
. 
Over half of these hypertension related deaths were preventable.
6
 
The Working Group of the NHBPEP- National High Blood Pressure 
Education Program (2000) classification of hypertensive disorders 
complicating pregnancy is as follows: 
1. Gestational hypertension 
2. Pre-eclampsia 
3. Eclampsia 
4. Pre-eclampsia superimposed on chronic hypertension 
5. Chronic hypertension 
An important feature of this classification is differentiating preeclampsia 
and eclampsia from other hypertensive disorders because the former two 
are potentially more ominous. This concept is also important to interpret 
and appreciate studies that address the etiology, pathogenesis, and clinical 
management of pregnancy related hypertensive disorders. 
 GESTATIONAL HYPERTENSION 
The diagnosis of gestational hypertension is made in women whose 
blood pressure reaches 140/90 mm Hg or greater for the first time after 
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mid pregnancy (20 weeks), but in whom proteinuria is not identified. 
Almost half of these women subsequently develop preeclampsia. 
Gestational hypertension is reclassified as transient hypertension if 
evidence for preeclampsia does not develop and the blood pressure 
returns to normal by 12 weeks postpartum. 
 PREECLAMPSIA 
It is a pregnancy specific syndrome that can affect virtually every 
organ. Proteinuria is the surrogate objective marker that defines the 
system wide endothelial leak. It is defined by 24-hour urinary protein 
excretion exceeding 300 mg, persistent 30 mg/dL (1+dipstick) protein in 
random urine samples.
7 
 ECLAMPSIA 
The onset of convulsions in a woman with preeclampsia that cannot be 
attributed to other causes is termed eclampsia. The seizures are 
generalized and may appear before, during, or after labor. 10 % of 
eclamptic seizures develop before overt proteinuria is identified.
8 
 ETIOPATHOGENESIS 
Gestational hypertensive disorders are more likely to develop in 
women who  
• Are exposed to chorionic villi for the first time. 
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• Are exposed to a superabundance of chorionic villi, as with twins 
or hydatidiform mole 
• Have preexisting renal or cardiovascular disease 
• Are genetically predisposed to hypertension developing during 
pregnancy. 
Regardless of precipitating etiology, the cascade of events that leads to 
the preeclampsia is characterized by a host of abnormalities that result in 
vascular endothelial damage and subsequent vasospasm, transudation of 
plasma, and ischemic and thrombotic sequelae. Recently preeclampsia 
has been considered as two stage disorder. Stage 1 faulty endovascular 
trophoblastic remodeling that downstream causes the stage 2 clinical 
syndrome.
9 
 Abnormal trophoblastic invasion 
In normal implantation, the uterine spiral arterioles undergo extensive 
remodeling as they are invaded by endovascular trophoblasts. These cells 
replace the vascular endothelial and muscular linings to enlarge the vessel 
diameter. In preeclampsia there may be incomplete trophoblastic 
invasion. With such shallow invasion myometrium, vessels are not lined 
by endovascular trophoblasts.
10
They do not lose endothelial lining and 
musculoelastic tissue, and their mean external diameter is only half that 
of vessels in normal placentas, abnormally narrow spiral arteriolar lumen 
impairs placental blood flow. The magnitude of defective trophoblastic 
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invasion of the spiral arteries correlates with the severity of the 
hypertensive disorder.  
 Immunological factors 
Diminished perfusion and a hypoxic environment eventually lead to 
release of placental debris that incites a systemic inflammatory response, 
results in dysregulation of immune tolerance . Formation of blocking 
antibodies to placental antigenic sites might be impaired. Beginning in 
early second trimester women who develop preeclampsia, Th1 action 
increased and the Th1/Th2ratio changes. Contributors to an enhanced 
immunologically mediated inflammatory reaction are stimulated by 
placental microparticles.
11 
 Endothelial cell activation 
Briefly, cytokines such as tumor necrosis factor-α(TNF-α), and the 
interleukins (IL) may contribute to the oxidative stress associated with 
preeclampsia. This is characterized by reactive oxygen species and free 
radicals that lead to formation of self-propagating lipid peroxides
12
. These 
in turn generate highly toxic radicals that injure endothelial cells, modify 
their nitric oxide production, and interfere with prostaglandin balance. 
These observations on the effects of oxidative stress in preeclampsia have 
given rise to increased interest in the potential benefit of antioxidants to 
prevent preeclampsia. Antioxidants are from a diverse family of 
compounds that function to prevent overproduction of and damage 
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caused by noxious free radicals. Dietary supplementation with 
antioxidants to prevent preeclampsia has thus far proven unsuccessful. 
 Genetic factors 
Preeclampsia is a multifactorial, polygenic disorder.  An incidence 
risk factor for preeclampsia is 20 to 40 percent for daughter of 
preeclampsia. Thus the phenotypic expression of inherited gene will 
differ depending on interactions with environmental factors. 
More than 70 genes have been studied for their possible association 
with preeclampsia. Seven of these have been investigated widely.
13 
 
GENETIC FACTORS: 
GENE FUNCTION 
AFFECTED 
CHROMOSOME 
MTHFR(C677T) Methylene 
tetrahydrofolate 
Reductase 
1p36.3 
F5(Leiden) Factor V 1q23 
AGT(M235T) Angiotensinogen 1q42-q43 
HLA(Various) Human Leukocyte 
Antigens 
6p21.3 
NOS3(Glu 298 Asp) Endothelial 
nitricoxide 
7q36 
F2(G20210A) Prothrombin 11p11-q12 
ACE Angiotensin 
converting enzyme 
17q23 
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 Increased pressor response to infused norepinephrine and 
angiotensin II in women with early preeclampsia. Normal pregnant 
women develop refractoriness to vasopressor. 
 
 Endothelial prostacyclin (PGI2) production decreases in 
preeclampsia. Thromboxane A2 increases. PGI2/TXA2ratio 
decreases. The net result favors increased sensitivity to infused 
angiotensin II and ultimately vasoconstriction. 
 
 Nitric oxide – potent vasodilator is synthesized from L-arginine by 
endothelial cells. Withdrawal of nitric oxide results in a clinical 
picture similar to preeclampsia in a pregnant animal model
14
. It 
appears that preeclampsia is associated with decreased endothelial 
nitric oxide synthase expression, thus increased nitric oxide 
inactivation. These responses may be race related.
15
 
 
 Soluble Fms –like tyrosine kinase 1(sFlt-1) is a variant of the Flt-1 
receptor for placental growth factor (PlGF) and vascular 
endothelial growth factor (VEGF). Increased maternal sFlt-1 levels 
inactivate and decreased circulating free PlGF, VEGF 
concentrations leading to endothelial dysfunction.
16
 
 
 Soluble endoglin (sEng) is a placenta- derived molecule that blocks 
endoglin which is a cofactor for TGF-β. This soluble form endoglin 
inhibits TGF hence decreased endothelial nitric oxide dependent 
vasodilatation.
17
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 Cardiac output in preeclampsia decreases likely due to increased 
peripheral vascular resistance. 
 
 Hemoconcentration is hallmark of preeclampsia. Generalized 
vasoconstriction that follows endothelial activation and leakage of 
plasma into the interstitial space. 
 
 THROMBOCYTOPENIA- it is common hence platelet count is 
routinely measured in any form of gestational hypertension. The 
frequency and intensity of thrombocytopenia vary and are 
dependent on the severity and duration of the preeclampsia. Overt 
thrombocytopenia defined by platelet count less than 1,00,000 
cells/µL – indicates severe disease. In general lower the platelet 
count, higher the rates of maternal and fetal morbidity and 
mortality
18
. In most cases delivery is advisable because 
thrombocytopenia continues to worsen. After delivery, the platelet 
count may continue to decrease for the first day or so. It then 
usually increases progressively to reach a normal level usually 
within 3 to 5 days. In some instances platelet count continues to 
fall after delivery like HELLP syndrome. 
 
 Other platelet abnormalities include platelet activationwith 
increased degranulation, thromboxane A2 release and in vitro 
platelet aggregation is decreased compared with the normal 
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increase characteristic of pregnancy.
19
This is likely due to platelet 
exhaustion following in vivo activation. Although the cause is 
unknown, immunological process or simply platelet deposition at 
sites of endothelial damage may be implicated.Platelet bound and 
circulating platelet–bindable  immunoglobulins are increased, 
which suggest platelet surface alterations. Severe 
thrombocytopenia does not develop in fetus or infant in 
preeclamptic women. 
 
 KIDNEY- during normal pregnancy blood flow and glomerular 
filtration  increase. With development of preeclampsia, there may 
be a number of reversible anatomical and pathophysiological 
changes. Renal perfusion and glomerular filtration are reduced. 
Glomerular endotheliosis blocking the filtration barrier. Intensive 
intravenous fluid management is not indicated for these women 
with oliguria, unless diminished urine output is caused by 
hemorrhage. Plasma uric acid is typically elevated in preeclampsia, 
due to reduction in filtration and enhanced tubular reabsorption. At 
least some degree of proteinuria will establish the diagnosis of 
preeclampsia. In 24-hour quantitative urinary specimen, the 
standard consensus threshold value used is>300 mg/24-hour. 
Urinary dip stick method is simple but with false positive and 
negative results. Worsening of proteinuria has been considered to 
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be a sign of severe disease, this may not be the case. It is currently 
being investigated. 
 
 LIVER- hepatic changes in women with fatal eclampsia were 
described in 1856 by Virchow. The characteristic lesions 
commonly found in the liver periphery. Hemolysis, hepatocellular 
necrosis, and thrombocytopenia were later termed as HELLP 
syndrome. 10 percent HELLP had concurrent eclampsia
20
. They 
have worse outcome than only with preeclampsia. Liver 
involvement in preeclampsia is clinically significant in following 
circumstances. 1. Symptomatic involvement, typically manifest by 
moderate to severe right upper or midepigastric pain and 
tenderness, is usually only seen with severe disease. 2. 
Asymptomatic elevations of serum hepatic transaminase levels 
AST and ALT are considered markers for severe preeclampsia. 
Values seldom exceed 500 U/L. they inversely follow platelet 
levels. Both usually normalize within 3 days following delivery. 3. 
Hepatic hemorrhage from areas of infarction may extend to form a 
hepatic hematoma. These in turn may extend to form a subcapsular 
hematoma that may rupture. They can be identified using CT or 
MRI. Management usually consists of conservative and 
observation. Very few cases may require prompt surgical 
intervention. 
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 BRAIN- headaches and visual symptoms are common with severe 
preeclampsia, and associated convulsions define eclampsia. 
Principle lesions found in eclamptic women were cortical and 
subcortical petechial hemorrhages. Other frequently described 
major lesions were subcortical edema. The classical microscopic 
vascular lesions consist of fibrinoid necrosis of the arterial wall and 
perivascular microinfarcts and hemorrhage. Two general theories 
to explain cerebral abnormalities associated with eclampsia. 
Importantly, endothelial dysfunction that characterizes the 
preeclampsia syndrome likely plays a key role in both: 1. Response 
to acute and severe hypertension, cerebrovascular overregulation 
leads tovasospasm.21Deminished cerebral blood flow is 
hypothesized to result in ischemia, cytotoxic edema, and 
eventually, tissue infarction.  2. Sudden elevations in systemic 
blood pressure exceed the normal cerebrovascular autoregulatory 
capacity.22 Forced vasodilation and vasoconstriction develops. At 
capillary level, disruption of hydrostatic pressure, hyperperfusion, 
and extravasation of plasma and red cells through endothelial tight-
junctions openings leading to vasogenic edema. Clinical 
manifestations include 1. Headache and scotoma are thought to 
arise from cerebrovascular hyperperfusion that has a predilection 
for the occipital lobes. 50 to 70 percent of women have headaches 
and 20 to 30 percent have visual changes preceding eclamptic 
convulsions. 2. Convulsions are diagnostic for eclampsia.               
 14 
 
3. Blindness is rare in preeclampsia but can in eclampsia. 4. 
Generalized cerebral edema may develop and is usually manifest 
by mental status changes that vary from confusion to coma. This 
situation is particularly dangerous because fatal supratentorial 
herniation may result. 
 
 MAGNESIUM LEVELS IN ECLAMPSIA-the role of serum 
electrolytes in PIH has been studied. For long time it is known that 
sodium retention can cause hypertension and sodium restricted diet 
is advised to hypertensive patient. The serum potassium is also 
measured in hypertensive patient to screen mineralocorticoid 
induced hypertension and to provide a baseline before beginning a 
diuretic therapy. Recently other two electrolytes namely calcium 
and magnesium is gaining importance in preeclampsia. The 
decrease in serum magnesium level in preeclampsia is reported.
23
 
Calcium and magnesium can regulate blood pressure in a 
neurohumoral, renal and adrenal machanism
24
, which can explain 
their decrease in preeclampsia. Magnesium is the 4
th
 most abundant 
cation in the body and is present in more than 300 enzymatic 
systems where it is crucial for ATP metabolism.
25
 Magnesium may 
influence blood pressure by modulating vascular tone and 
structured through its effects on myriad biochemical reactions that 
control vascular contraction/dilation, growth/apoptosis, 
differentiation and inflammation. Magnesium acts as calcium 
channel antagonist. It stimulates production of vasodilator 
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prostacyclin and nitric oxide and alters vascular responses to 
vasoconstrictors agents. Its deficiency level can also play a role in 
hypertension in pregnancy.
26
Regarding magnesium there are lots of 
contrast studies. Some studies do not support the hypothesis that 
low serum magnesium is a risk factor for developing hypertension 
and vascular dysfunction.
27
 
1. Magnesium modulates the cardiovascular effect of sodium and 
potassium and it is the co-factor for the sodium-potassium ATPase 
activity.
28
 
2. It affects the cardiac and smooth muscle cells by altering the 
transport of calcium and its binding to the membrane and organ 
cells.                                                                                         
3.
 It acts peripherally to produce peripheral vasodilatation and a fall 
in blood pressure. Thus, low levels of magnesium predispose to an 
increase in the arterial pressure.
29 
4. It is known to increase the prostacyclin release from the endothelial 
cells of the blood vessels, which acts as a potent vasodilator. 
Magnesium depletion increases the vasoconstrictor effect of 
angiotensin II and nor-adrenaline.                                                    
5. Magnesium also has a substantial beneficial effect in preeclampsia 
for the prevention and treatment of convulsions. Therapeutic 
magnesium sulphate which is used in PIH inhibits 
phosphatidylinositol-4,5-bisphosphonate specific phospholipase c 
activity and subsequent calcium release in the cells, thus leading to 
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decreased intracellular calcium levels and a decrease in blood 
pressure.                                                                                     
6. Hemodilution effect of estrogen and increased demand of fetus 
decreases the serum magnesium level and in preeclampsia urinary 
excretion of magnesium also increases so the level decreases 
further.
30
 
7. Magnesium deficiency causes hemodynamic abnormalities such as 
arterial wall thickening, abnormal vascular tone and endothelial 
dysfunction which are due to alteration in the biology of cellular 
and non-cellular components of arterial wall. There may be a 
causal relationship between hypomagnesaemia and preeclampsia 
since magnesium is involved in blood pressure regulation through 
an intracellular inhibition of NO synthase in endothelial cells.
31
 
 
 RISK FACATORS 
 AGE- risk of preeclampsia/eclampsia is increased at the extremes 
of reproductive age. 20-29 years, young primipara women. 
Maternal age over 40 years is associated with double the risk of 
preeclampsia irrespective of parity.32 
 
 PARITY- primigravida have 15 times greater risk compared to 
multigravida  of developing preeclampsia.
33
Although at a lower 
risk for developing preeclampsia multiparous women often develop 
severe forms of the disease and are at a higher risk of developing 
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severe morbidity such as eclampsia, renal failure, and pulmonary 
edema and hence higher mortality.
34
 
 
 PREVIOUS PREECLAMPSIA- history of preeclampsia in the 
previous pregnancy is a strong predictor of recurrence of the 
disease.  Risk in a subsequent pregnancy to be increasing by more 
than 6 times.
35
Early onset preeclampsia run a greater risk of 
recurrence. It has been observed that there is an increased 
incidence of preeclampsia with a different partner or donor sperm 
pregnancy meaning that every first pregnancy with a new partner is 
at greater risk. 
 
 LONG BIRTH INTERVAL- the risk of preeclampsia in a 
multipara is found to be directly related to the time elapsed since 
the last delivery. If the interval between 2 pregnancies was more 
than 10 years the risk of preeclampsia is equaled the risk in 
primigravidas.
36
 
 
 GENETIC FACTOR- a positive family history is a known risk 
factor as it is observed that the daughters of eclamptic women are 
at eight times higher risk of developing preeclampsia and hence 
has a genetic predisposition.
37
 
 
 MULTIPLE PREGNANCY- it is a high risk for developing 
preeclampsia. Risk for preeclampsia is four times in twin 
pregnancies compared to singletons.
38
It was found that the risk was 
irrespective of the chorionicity and zygosity. 
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 ASSISTED REPRODUCTION- has a higher risk of preeclampsia 
because of the higher incidence of multiple pregnancies. Gamete 
donation found to increase the risk of preeclampsia. Women who 
conceived with donor sperm, donor oocytes or donated embryos 
showed that the rate of preeclampsia was increased to 18.1 percent 
compared with controls who consisted of women who either 
conceived spontaneously or with intrauterine insemination with 
husband’s sperm.
39
 
 
 OBESITY-it is an established risk factor by itself.
40
In addition it is 
one of the components of syndrome X, the other components of 
this medical disorder being type II diabetes and hypertension. It has 
been established that the waist circumference in early pregnancy 
which is a measure of central obesity especially when associated 
with insulin resistance is directly associated with preeclampsia.
41
 
 
 PRE-EXISTING HYPERTENSION-Incidence of preeclampsia is 
much higher in women with chronic hypertension. The risk of 
preeclampsia is related to degree of hypertension. Superimposed 
preeclampsia is 46 percent in severe hypertension (diastolic of 110 
mmHg or more) as against an incidence of 14 percent among those 
with mild hypertension (diastolic BP 90-119 mmHg).
42
 
 DIABETES MELLITUS- risk of preeclampsia is roughly doubled 
by diabetes. Pre-existing diabetes mellitus are at greater risk than 
with those having GDM. As in hypertension risk is proportionate to 
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degree of DM. women with micro vascular complications are at 
higher risk than those without it.
43
 
 
 DYSLIPIDAEMIA- It has been observed that preeclampsia is 
associated with increased triglyceride synthesis by the liver and 
decreased catabolism of the same at the periphery leading to 
elevated triglyceride levels. It is thought that adipocyte lipolysis 
which is a feature of normal pregnancy that leads to elevated non-
esterified fatty acids is exaggerated in women destined to develop 
preeclampsia. Elevated NEFA concentrations in general, cause 
dyslipidemia in human causing hypertriglyceridemia. It also 
enhances oxidative stress, inflammation and endothelial 
dysfunction, features characteristics of pathogenesis of 
preeclampsia.
44
Probably women destined to develop preeclampsia 
possess a preexisting lipolytic defect. Similar situation is seen in 
individuals with central obesity. 
 
 THROMBOPHILIA- whether hereditary or acquired, 
thrombophilia is a well-established high risk 
factor.
45
Antiphospholipid syndrome characterized by the presence 
of antibodies like lupus anticoagulant and/or anticardiolipin 
antibodies in association with clinical history suggestive of 
thrombosis or adverse pregnancy outcome is a high risk factor for 
development of preeclampsia. Thrombophilia, there is definite 
association with early onset preeclampsia.
46
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 Smoking is found to be associated with reduced incidence of 
preeclampsia though otherwise it is associated with a higher 
perinatal loss.
47
Stress is another important factor that predisposes 
to the development of preeclampsia. 
 
 Certain placental and fetal factors have a bearing on the occurrence 
of preeclampsia. A large placenta as is often seen in multiple 
pregnancy, placental hydrops and molar pregnancy are associated 
with higher incidence of preeclampsia. Certain chromosomal 
defects like triploidy, trisomy 13, and trisomy 16 mosaicism are 
also frequently associated with preeclampsia. All conditions 
associated with poor placentation have a higher risk of developing 
preeclampsia. 
 
 
 PREDICTORS OF PREECLAMPSIA 
 Measurement of variety of biological, biochemical, and 
biophysical markers implicated in the pathophysiology of preeclampsia 
has been proposed to predict its development. Attempts have been made 
to identify early markers of faulty placentation, impaired placental 
perfusion, endothelial cell activation and dysfunction, and activation of 
coagulation. But unfortunately these testing strategies are with poor 
sensitivity and with poor positive predictive value for preeclampsia. 
However, combinations of tests, some yet to be adequately evaluated, that 
may be promising. Most of the testingare cumbersome and time 
consuming. 
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 PROVOCATIVE PRESSOR TESTS- there are three tests 
extensively evaluated to assess blood pressure increase in response 
to a stimulus. The “roll over test” measures the hypertensive 
response in women at 28-32 weeks who are resting in the left lateral 
decubitus position and the “roll-over” to assume a supine position. 
The isometric exercise test employs the same principle by squeezing 
a handball. The angiotensin II infusion test is performed by giving 
incrementally increasing doses intravenously, and the hypertensive 
response is quantified. All three tests found to have sensitivities 
ranging 55-70 percent and specificities approximately 85 percent.
48
 
 
 UTERINE ARTERY DOPPLER VELOCIMETRY- faulty 
trophoblastic invasion of the spiral arteries. This results in 
decreased placental blood flow and increased uterine artery 
impedance in upstream. Increase flow resistance results in an 
abnormal waveform represented by an increased diastolic notch.  
 
 PULSE WAVE ANALYSIS- finger arterial pulse “stiffness” is an 
indicator of cardiovascular risk. Investigations have evaluated its 
usefulness in preeclampsia prediction.
49
 
 
 ENDOCRINE DYSFUNCTION-number of serum analyses that 
have been proposed to help predict preeclampsia are human 
chorionic gonadotropin (hCG), alpha-fetoprotein (AFP), estriol, 
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pregnancy associated protein A (PAPP A), Inhibin A, activin A, 
placental protein 13, corticotrophin releasing hormone. 
 
 SERUM URIC ACID-it is one of the earliest laboratory 
manifestations of preeclampsia. It is likely results from reduced uric 
acid clearance from diminished glomerular filtration, increased 
tubular reabsorption, and decreased secretion. But they have very 
low sensitivity and specificity. 
 
 Microalbuminuria and urine albumin:creatinine ratio have 
unacceptable sensitivity and specificity.
50
 
 
 FIBRONECTINS-these high molecular weight glycoproteins serve 
a variety of cellular functions that include adhesion and 
morphology, migration, phagocytosis, and 
hemostasis.
51
Fibronectins are released from endothelial cells and 
extracellular matrix following endothelial injury. Recent studies 
concluded that neither cellular nor total fibronectins was clinically 
useful to predict preeclampsia.
52
 
 
 COAGULATION ACTIVATION- thrombocytopenia and platelet 
dysfunction are integral features of preeclampsia. Platelet activation 
causes increased destruction and decreased concentrations. Mean 
platelet volume increases because of young platelet age. Although 
markers of coagulation activation are increased, there is a 
substantiate overlap between normal pregnancies. 
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 OXIDATIVE STRESS- increased levels of lipid peroxidases 
coupled with decreased antioxidant activity have raised the 
possibility that markers of oxidative stress might predict 
preeclampsia.
53
 Malondialdehyde is a marker of lipid peroxidation. 
Other pro-oxidation markers include iron, transferrin, and ferritin, 
free fatty acids, triglycerides.
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 ANGIOGENIC FACTORS- an imbalance between proangiogenic 
and antiangiogenic factors is related to the pathogenesis of 
preeclampsia. Proangiogenic factors like vascular endothelial 
growth factors, placental growth factors begin to decrease before 
clinical preeclampsia develops. Antiangiogenic factors like soluble 
fms-like tyrosine kinase -1, soluble endoglin are increased.
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 FREE FETAL DNA-using polymerase chain reaction, free fetal 
DNA can be detected in maternal plasma. It is hypothesized that 
free DNA is released by accelerated apoptosis of cytotrophoblast.
56
 
 
 PREVENTION 
o LOW SALT DIET- one of the earliest research efforts to prevent 
preeclampsia was salt restriction.
57 
But randomized control trial 
showed that a sodium restricted diet was ineffective in preventing 
preeclampsia.58 
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o CALCIUM SUPPLEMENTATION- women with low dietary 
calcium intake were at significantly increased risk for gestational 
hypertension. Trials have shown that unless women are calcium 
deficient, supplementation has no salutary effects.
59
 
 
o FISH OIL SUPPLEMENTATION- the most common dietary 
sources are eicosapentaenoic acid and alpha-linoleic acid. With 
proclamations that supplementation with these fatty acids would 
prevent inflammatory mediated atherogenesis, it was not a 
quantum leap to posit that they might prevent preeclampsia.
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o ANTIHYPERTENSIVE DRUGS- women given diuretics had a 
decreased incidence of edema and hypertension, but not of 
preeclampsia. Because women with chronic hypertension are at 
high risk for preeclampsia, antihypertensive drugs reduce the 
incidence of superimposed preeclampsia. 
 
o ANTIOXIDANTS- there are inferential data that an imbalance 
between oxidant and antioxidant activity may have an important 
role in the pathogenesis of preeclampsia. Vitamin C & E may 
decrease such oxidation. Moreover, women who developed 
preeclampsia were found to have reduced plasma levels of these 
two vitamins.
61
Thus dietary supplementation was propose as a 
 25 
 
method to improve the oxidative capability of women at risk for 
preeclampsia. 
o LOW-DOSE ASPIRIN- 50-150 mg daily, aspirin inhibits 
effectively platelet thromboxane A2 biosynthesis with minimal 
effects on vascular prostacyclin production.
62
In meta-analysis of 
31 randomized trials, for women received antiplatelet agents, 
relative risk of preeclampsia was decreased significantly by 10 
percent for development of preeclampsia, superimposed 
preeclampsia, preterm devlivery.
63
The number needed to treat was 
high. Because of marginal benefit, it seems reasonable to 
individualize use of low-dose aspirin to prevent preeclampsia. 
Collaborative Low Dose Aspirin Study in Pregnancy (CLASP), a 
large randomized controlled trial reported a reduction of 12% in 
preeclampsia. 
 
o LOW-DOSE ASPIRIN PLUS HEPARIN- because of high 
prevalence of placental thrombotic lesions found with severe 
preeclampsia, there have been several observational trials to 
evaluate heparin treatment for affected women. Prophylaxis with 
low-molecular-weight heparin plus low-dose aspirin on pregnancy 
outcomes in women with a history of severe early-onset 
preeclampsia and low-birth weight infants. There were better 
pregnancy outcomes in women given low-dose aspirin plus low-
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molecular-weight heparin compared with those given low-dose 
aspirin alone.
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CLINICAL FEATURES OF ECLAMPSIA: 
 Headache – persistent occipital or frontal headaches 
 Visual disturbance – blurred vision and photophobia. 
Examination of the optic fundi will show marked retinal edema 
and in the severe stages haemorrhage, exudates and papilledema 
may also be present. 
 Restless and agitation 
 Epigastric and/or right upper quadrant pain 
 Nausea and vomiting 
 Oliguria 
 Laboratory evidence of disseminated intravascular coagulation 
 
MATERNAL COMPLICATION: 
o Abruptio placenta is an important complication of hypertension 
in pregnancy and a massive unheralded bleed can have 
disastrous consequences. 
o Cerebrovascular accident – usually intracerebral haemorrhage, 
occasionally ruptured intracranial aneurysm or cerebral 
thrombosis. This may be fatal or the woman may be left with a 
 27 
 
residual neurological deficit such as hemiplegia, dysphasia or 
visual disturbance. 
o HELLP syndrome- hemolytic anemia, elevated liver enzymes, 
low platelets 
o Acute left ventricular failure with pulmonary edema 
o Aspiration pneumonia 
o Acute renal failure 
o Microangiopathic hemolyticanemia. The patient usually has 
evidence of severe widespread intravascular coagulation, which 
may be associated with eclampsia, renal failure, hepatic failure, 
cerebral thrombosis and circulatory collapse. 
o Cardiopulmonary arrest. 
 
 FETAL COMPLICATIONS 
o Intrauterine death  
o Intrauterine growth restriction. It does not appear to be related 
to the actual level of blood pressure, the duration of 
hypertension and the presence of proteinuria being more 
important factors 
o Prematurity and its hazards: neonatal death, pulmonary, renal 
and hepatic dysfunction. Early labour may occur 
spontaneously, abruption, iatrogenic. 
o Antepartum and intrapartum asphyxia is more likely to be due 
to anoxia associated with poor placental blood flow, maternal 
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hypoxia induced by eclampsia or excessive therapy with 
sedatives and anticonvulsants. 
o Neonatal encephalopathy – a systemic inflammatory response 
in the fetus, perhaps secondary to oxidative stress, could 
explain the link between maternal preeclampsia and neonatal 
encephalopathy, and this may occur through cerebral 
vasoconstriction. 
o Effect of magnesium sulphate- hypermagnesaemia is seen. 
Lethargy, hypotonia, apnoea, respiratory depression, poor 
sucking reflex, decreased intestinal motility and delayed 
passage of meconium. 
 
 MANAGEMENT OF ECLAMPSIA: 
 In a patient who is convulsing or just had a convulsion, the first 
priority is to avoid maternal injury and immediate attention to 
the airways.  
 The patient should be nursed in the left lateral position and any 
secretions or vomitus suctioned to avoid aspiration. 
 A padded tongue blade or airway is inserted between the teeth 
to avoid tongue bite and maintain airway.  
 Oxygen should be given by mask at 8-10 L/min to correct 
maternal and fetal hypoxia, and the oxygen saturation 
monitored with a transcutaneous pulse oximeter.  
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 Arterial blood gas analysis is indicated if the oximeter shows a 
saturation <92%. 
 An intravenous access is secured and treatment commenced to 
prevent recurrent seizures and control blood pressure.  
 Once the patient is a little stable and not restless, she should be 
catheterized with an indwelling catheter and a vaginal 
examination performed to access the cervical status. 
 
 CONTROL OF SEIZURES: 
MAGNESIUM SULPHATE - The drug of choice for the control of 
seizures in eclampsia is magnesium sulfate.
65
A total loading dose of 14 g 
is given, 4 g as intravenous infusion (20 ml of 20 % solution) over 15 to 
20 minutes and 10 g deep intramuscular, 5 g in each buttock (10 ml of 50 
% solution).This is followed by 5 g intramuscularly every 4 hours. 
 
Magnesium toxicity can lead to respiratory paralysis, cardiac 
conduction defects and cardiac arrest. It is however rare in clinical 
practice provided the drug is administered with proper monitoring.The 
suggested therapeutic plasma level of magnesium sulfate for treatment of 
eclamptic convulsions is 1.8-3.0mmol/L.The first sign of impending 
toxicity occurs with loss of patellar reflex which corresponds to a plasma 
level of 3.5-5mmol/L.Therefore, repeat doses should be given only if the 
patellar reflex is present, respiratory rate is greater than 12 per minute and 
urine output has been greater than 100 ml in previous 4 hours.Routine 
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monitoring of serum magnesium levels is not required when these signs 
are monitored, although it is desirable in women with impaired renal 
function who are at greater risk of magnesium toxicity.If a patient 
develops signs of toxicity, magnesium should be immediately 
discontinued, oxygen should be administered and serum magnesium level 
obtained.10 ml of 10% calcium gluconate solution should be infused 
slowly over a period of 3 minutes if magnesium toxicity occurs. Other 
anticonvulsant drugs and regimens which were used commonly for the 
treatment of eclamptic convulsions before magnesium sulphate became 
popular include phenytoin, diazepam and the “lytic cocktail”. 
 
 CONTROL OF BLOOD PRESSURE: 
Persistent and severe elevation in blood pressure (>= 160/110 mm Hg) 
should be treated to prevent cerebro-vascular accidents, pulmonary 
edema and renal failure. The hypertensive crisis is managed by acute-
acting anti-hypertensives. 
 
 DELIVERY 
The definitive treatment of eclampsia is delivery, irrespective of 
gestational age. Once the mother is stabilized, the status of the fetus is 
assessed. Fetal bradycardia lasting for 3 to 5 minutes is common 
observation during and immediately after an eclamptic seizure and does 
not necessitate an emergency caesarean delivery. However fetal 
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bradycardia lasting for 10 minutes necessitates evaluation for uterine 
hyperstimulation or placental abruption. The gestational age, cervical 
status, fetal condition and position need to be considered before 
determining the most appropriate route of delivery. Vaginal delivery is 
safe option resulting in low maternal mortality rates as long as fetal 
presentation and status are appropriate and labour progresses in an 
orderly fashion. Cervical ripening agents can be used to improve the 
Bishop score. Prolonged inductions should however be avoided.  
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MATERIALS AND METHODS 
PATIENTS AND METHODS 
All the patients admitted with eclampsia at the obstetric and 
gynecological department of Coimbatore Medical College Hospital, 
Coimbatore between 1
st
 of March 2010 to 30
th
 of June 2011, who fulfill 
the inclusion criteria were included as study population.  
Forms which captured the required clinical information were used. 
Such information used included age, parity, booking status, gestational 
age at presentation, time of onset of fits (antenatal, intrapartum, post 
natal), blood pressure at time of fits / arrival at the hospital. Biochemical 
parameters included platelet count, serum magnesium level. Treatment 
modality employed, mode of delivery, fetal morbidity and mortality, 
maternal morbidity and mortality were recorded. 
INCLUSION CRITERIA 
Patients with generalized tonic-clonic convulsions during 
pregnancy / labour / within 7 days of delivery were included. 
EXCLUSION CRITERIA 
 Previous history of epilepsy 
 Previous history of neurological disorders 
 Features suggestive of encephalitis/ meningitis 
 Any other secondary causes underlying seizures 
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WORKING DEFINITIONS: 
ECLAMPSIA – women with convulsions associated with signs of 
preeclampsia during pregnancy, labour or within 7 days of delivery, not 
attributed to other causes of seizures. 
BOOKED PATIENTS - those who were registered at any health care 
providers for antenatal care and delivery (PHC/District 
hospitals/institutions/private hospitals). 
ANTEPARTUM ECLAMPSIA- seizures occurring in preeclamptic 
women after 20 weeks of gestation before onset of labour. 
INTRAPARTUM ECLAMPSIA - seizures occurring in pregnant 
women during labour. 
POSTPARTUM ECLAMPSIA - seizures occurring after delivery and 
within seven days postpartum. 
RECURRENCE OF FITS – considered when seizure occurs even after 
starting magnesium sulphate regimen. 
BLOOD PRESSURE – taken in right arm, left lateral position, first and 
fifth korotkofff sound was taken as systolic and diastolic blood pressure 
at the time of admission. 
PLATELET COUNT – normal range 1,50,000 – 3,00,000 cells/µL. 
overt thrombocytopenia when platelet count < 1,00,000 cells/µL. 
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SERUM MAGNESIUM LEVEL – sample taken on admission, before 
starting magnesium sulphate regimen.Normal value 1.8 – 3.0 mg/dl. 
HELLP SYNDROME – hemolysis (schistocytes in blood smear, 
bilirubin >1.2 mg/dl), low platelet (<1 lakh) and elevated liver enzymes 
(AST ≥72IU/L, LDH >600 IU/L). All three parameters should be present 
for a diagnosis of HELLP syndrome. 
PULMONARY EDEMA – diagnosis is made clinically in a woman with 
tachypnea, tachycardia, lung signs such as crepitation and with or without 
fall in saturation, in the absence of other explainable causes. 
CEREBRAL HEMORRHAGE – diagnosed with CT brain imaging. 
RENAL FAILURE – decreased urine output of <30 ml/hr for more than 
6 hours in spite of fluid challenge if the patient was not susceptible to 
pulmonary edema, elevated creatinine of >1.2mg/dl. 
STILL BIRTH OR FETAL DEATH – the absence of signs of life at or 
after birth. 
EARLY NEONATAL DEATH  – death of a live born neonate during 
the first 7 days after birth. 
PERINATAL MORTALITY RATE – the number of stillbirths plus 
early neonatal deaths per 1000 total births. 
SMALL FOR GESTATION – below 10
th
 percentile of growth for that 
gestational age using WHO nomogram chart. 
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IUGR – fetus less than 10
th
 percentile of growth for that gestational age 
and with corroborative signs of compromised intrauterine environment 
such as oligohydramnios or an elevated head-abdomen circumference 
ratio, clinically loss of subcutaneous fat, loose skin folds, a wasted 
appearance. 
PROTOCOLS FOR MANAGEMENT OF ECLAMPSIA AT CMCH 
 On admission air ways and intravenous lines secured 
 Foley’s either inserted into bladder 
 Convulsions controlled with intravenous loading dose magnesium 
sulphate (Pritchard’s regimen) 
 Further convulsions after initiation of treatment controlled with an 
intravenous bolus of 2 grams of MgSO4 
 Hypertension controlled with antihypertensives, alphamethyldopa 
and nifidipine (through ryles tube if patient unconscious) 
 Baseline investigations include complete blood cell count, serum 
urea, creatinine, liver function test and platelet count, serum 
electrolytes (including serum magnesium). 
 Pregnancy was terminated irrespective of gestational age. Pelvic 
assessment and Bishop’s scoring done. Labour accelerated if 
patient had spontaneous labour. Induction was given for 
unfavorableBishop’s score. LSCS done for obstetrical indications. 
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 After delivery, patientskept under close monitoring 
andMgSO4regimen should be continued for 24 hours since last 
seizure or delivery depending on which occurred last. 
 48 hours after last fit and diastolic BP less than 100 mm Hg 
patients were shifted out of ICU and monitored in postnatal ward 
till discharge. 
 
 Mothers were followed up till discharge and all babies referred to 
the neonatal ward were followed up for 7 days to collect data on 
perinatal complications, early neonatal deaths and cause of 
neonatal deaths. Cause of maternal death was selected from the 
case notes as recorded by the doctor who certified the death. A 
post-mortem examination was not performed. The admission book 
was used to check if all admitted cases were included. 
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RESULTS AND ANALYSIS 
STASTICAL ANALYSIS 
 All the data were analyzed with SPSS software (version 13.0). 
Categoricalvariables were compared by Chi square test (χ
2
) or Fischer 
exact test and continuous variables were presented as mean ± SD and 
were compared by student “t” test. A probability value of <0.05 was 
considered statistically significant. 
RESULTS AND ANALYSIS 
INCIDENCE: 
 Patients included in the study were those with the diagnosis of 
eclampsia, admitted in labour ward ICU between first of March 
2010 and 30
th
 of June 2011.  
 There were total of8405 deliveries during the study period. 
 104 eclamptic patients were admitted. This accounts for 124 per 
10,000 deliveries 
 Incidence of eclampsia at CMCH during the study period was 
1.23%. 
 101 singleton and 3 twin deliveries. 
This is shown in the figure: 1 
 
 
FIGURE: 1 INCIDENCE OF ECLAMPSIA
AGE: 
Figure: 2show Age Distribution of Eclamptic patients.
The age range from 16 to 
58% of the patients were between 21 to 25 years, peak incidence occurred 
in this group. 
75% of the patients were less than 25 years.
Teenage pregnancy accounts for 11
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FIGURE: 2 AGE DISTRIBUTION 
 
 
TABLE: 1 AGE DISTRIBUTION 
AGE IN YEARS NUMBERS (n=104) PERCENTAGE (%) 
15 – 20 18 17% 
21 – 25 60 58% 
26 – 30 23 22% 
31 – 35 2 2% 
36 – 40 1 1% 
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BOOKING STATUS 
 Booked patients with regular antenatal checkup(ANC) - 68 
 Booked patients with improper ANC follow up    - 27 
 Unbooked patients           - 9 
Among those patients with intrauterine fetal demise (n=24),only 40% 
had regular antenatal checkup.  
Perinatal complications were considerably high in those with either 
irregular ANC or unbooked patients constituting 55%. 
27% of patients with maternal complications never been had any 
antenatal visits. 
IMMINENT SYMPTOMS BEFORE ECLAMPSIA: 
Among 104 eclamptic patients 80 of them had imminent symptoms 
before onset of seizures. 11 patients did not have symptoms and 13 
patients could not recollect the event before seizures. 
HEADACHE- The most common symptom prior to eclampsia, 
predominantly in occipital region.Usually occur at least 6 hours before 
the onset of seizures. In some it had been for 3 to 4 days. 80 women 
with eclampsia had headache (77%). 
VOMITING – it usually follows headache rather than occurring as 
isolated sign of imminent eclampsia. 22 patients out of eighty women 
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with symptoms of imminent eclampsia had vomiting along with 
headache. 
BLURRING OF VISION – was present in 7 patients. Of which one 
had retinal detachment in one quadrant and resolved in one week after 
delivery.  
OLIGURIA – 3 patients had decreased urine output before 
occurrence of eclampsia. among them 2 had renal failure. 
EPIGASTRIC PAIN – one of the patients had epigastric pain as an 
imminent symptom. 
Percentage of women with imminent symptoms has been given in the 
table: 2. 
TABLE : 2 IMMINENT SYMPTOMS OF ECLAMPSIA 
IMMINENT SYMPTOMS PERCENTAGE 
HEADACHE 77% 
VOMITING 21% 
BLURRED VISION 7% 
OLIGURIA 3% 
EPIGASTRIC PAIN 0.96% 
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CLINICAL FINDINGS AT PRESENTATION 
Clinical findings at the time on arrival at the hospital are listed in 
table: 3. 
The majority of the patients had seizures several times before 
arrival at the hospital and only 34 (32.6%) of the patients arrived in 
the hospital within six hours of onset of convulsions.  12 patients had  
≥ 5 seizures episodes, of which seven patients had been referred from 
places other than Coimbatore district. These patients had either no 
loading dose of magnesium sulphate or improper loading dose before 
referring. Two patients had native treatment in the form of heat 
application on forehead. 
Ninety one patients had pedal edema (87.5%). Two patients had 
anemia (1.2%). 
Totally 98 patients were in postictal drowsiness or confusion on 
admission (94.2%). 
  Ninety five patients had proteinuria on admission (91.3%). 
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TABLE : 3 CLINICAL FINDINGS 
SIGNS 
NO OF PATIENTS 
(Total patients 
n=104) 
PERCENTAGE 
Seizures ≥5 episodes 12 11.5% 
Pedal edema 91 87.5% 
Post ictal drowsiness/ 
confusion at 
admission 
98 94.2% 
 Anemia 2 1.9% 
Proteinuria 95 91.3% 
 
PARITY: 
As mentioned in all studies, most of them were primigravida. This 
accounted for 76%, whereas multigravida- 24%. 
Parity distribution is illustrated in table: 4 as follows. 
Among the multipara (n= 25) 15 had previous history of gestational 
hypertension /preeclampsia.  
 One had recurrence of eclampsia and 1 had chronic hypertension. One 
patient had history of second marriage where previous pregnancy was 
uneventful. 
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TABLE : 4 PARITY 
PARITY NUMBER (n=104) PERCENTAGE 
PRIMIGRAVIDA 79 76% 
G2P1 16 15% 
G3P2 5 5% 
G4P3 and above 4 4% 
 
TYPE OF ECLAMPSIA: 
Classification of eclampsia is based on onset of fit relative to delivery. 
Antepartum Eclampsia contributed 81% (n = 84) of total cases.  
While 6 (6%) had intrapartum and 14(13%) in postpartum period. 
In this study none had seizures beyond 48 hours of delivery irrespective 
of mode of delivery. 
Classification of eclampsia by onset of fits has been depicted in figure: 3. 
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FIGURE: 3 TYPE OF ECLAMPSIA 
 
BLOOD PRESSURE: 
Twenty patients had diastolic blood pressure >110 mm Hg on admission. 
Nine patients had systolic blood pressure of more than or equal to 180 
mm Hg. 
Average diastolic pressure 103.38 ± 12.74 mm Hg 
Systolic pressure on an average 156.25 ± 15.71 mm Hg 
Three patients were normotensive on admission. 
The diastolic pressure as a continuous variability has been put up in  
table: 5. 
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TABLE: 5 DIASTOLIC BLOOD PRESSURE AT THE TIME 
OF ADMISSION. 
BP in mm Hg NUMBER (104) PERCENTAGE 
≤90 8 7.69% 
91 – 100 27 25.96% 
101 – 110 49 47.11% 
111 – 120 18 17.30% 
121 – 130 2 1.91% 
 
TABLE: 6 SYSTOLIC BLOOD PRESSURE AT THE TIME 
OF ADMISSION 
BP in mm Hg NUMBER (104) PERCENTAGE 
≤ 140 18 17.30% 
141 – 150 25 24.03% 
151 – 160 24 23.07% 
161 – 170 18 17.30% 
171 – 180 15 14.42% 
≥ 181 4 3.84% 
 
GESTATIONAL AGE: 
Onset of eclampsia less than 24 weeks of gestation was found in three 
patients, of which one known to have chronic hypertension. 
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Eighteen (17%) patients had eclampsia at term, gestational age ≥37 
weeks. 
Gestational age at admission was more than 32 weeks in 75 (73%) 
patients. 
Fifty patients had disparity in their gestational age and their clinical 
examination.   
Gestational age of the patients on admission in weeks has been put up in 
table: 7. 
TABLE :7 GESTATIONAL AGE DISTRIBUTION 
GESTATIONAL 
AGE IN WEEKS 
NUMBER(104) PERCENTAGE 
<24 3 3% 
25-32 26 25% 
33-36 57 55% 
≥37 18 17% 
 
MODE OF DELIVERY: 
Figure: 4 project the mode of delivery in eclampsia patients. 
Fifty Nine (57%) had successful vaginal delivery. 
Forty four (42%) patients had Lower Segment Caesarian Section.  
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Indications included were failed induction (10), unfavorable cervix (16), 
and fetal distress (18). 
 
FIGURE: 4 MODE OF DELIVERY 
 
DEMOGRAPHIC CHARACTERISTICS – IN RELATION TO 
TYPES OF ECALMPSIA: 
 The demographic analysis of the study population in relation to types 
of eclampsia would be useful in comparing the outcome and to derive the 
recommendations at various level of health care providing system. 
 Age group distribution and occurrence of eclampsia types on 
analysis showed not much of significance in antepartum eclampsia. 
82%(64) of women ≤25 years and 76%(20) of women >25 years had 
57%
1%
42%
MODE OF DELIVERY
VAGINAL (59) FORCEPS (1) LSCS (44)
 49 
 
antepartum eclampsia. 78% (11) of postpartum eclampsia had women 
≤25 years. 
Twenty one multipara (84%) had antepartum eclampsia against 79%(63) 
of primigravida had antepartum eclampsia. 
Systolic blood pressure more than 160 mmHg were 37 in numbers, of 
which 33 had antepartum eclampsia. These features are shown in table: 8. 
TABLE: 8 DEMOGRAPHIC CHARACTERISTICS – TYPE OF 
ECLAMPSIA 
CHACTERISTICS ANTEPARTUM INTRAPARTUM POSTPARTUM 
Age ≤25 (n=78) 64 3 11 
Age >25 (n=26) 20 3 3 
Diastolic BP >110 
(n=20) 
19 1 NIL 
Systolic BP>160 
(n=37) 
33 1 3 
Primigravida (n=79) 63 3 13 
Multigravida (n=25) 21 3 1 
 
PLATELETS: 
Fifty nine patients had thrombocytopenia, of which 30 patients had overt 
thrombocytopenia (<1 lakh). 45 patients had normal platelet count. 
Platelet count in eclamptic patients has been shown in table: 9. 
 50 
 
TABLE:9 PLATELET COUNT IN ECLAMPSIA. 
PLATELET COUNT NUMBERS (104) PERCENTAGE 
< 50,000 3 3% 
50,000-1,00,000 27 26% 
1,00,000-1,50,000 29 28% 
>1,50,000 45 43% 
 
SERUM MAGNESIUM LEVEL: 
Serum magnesium level was measured in all eclamptic patients on 
admission. 
The mean value of serum magnesium in eclamptic women studied was 
1.74 ± 0.28 (mean ± SD). This was significantly lower than the normal 
value of 1.8 – 3.0 mg/dl, (p < 0.05).  
Those with maternal complications the serum magnesium levels were 
1.41 ± 0.15. This was statistically significant of p <0.001 (t value- 10.25). 
Patients without complications of eclampsia had magnesium level of 1.84 
± 0.16. 
Magnesium level in those who had recurrence of seizures (47.6%) is 1.60 
± 0.12. 
Serum magnesium level associated with and without complications is 
shown in table: 10. 
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TABLE: 10 SERUM MAGNESIUM LEVEL 
Normal magnesium level 1.8 – 3.0 mg/dl 
Average of total patients  (n=104) 1.74 ± 0.28 mg/dl 
With complications (n=18) 1.41 ± 0.15 mg/dl 
Without complications (n=86) 1.84 ± 0.16 mg/dl 
Recurrence of seizures (n=49) 1.60 ± 0.12 mg/dl 
 
FETAL OUTCOME: 
BIRTH WEIGHT: 
Birth weight of all neonates irrespective of outcome was recorded. This is 
shown in table: 11. 
Sixty One  neonates were with birth weight ≤ 2kg. 
Only 17 were above 2.5Kg birth weight. 
One hundred and one(101) singleton and 3 twins were delivered, total of 
107 babies. Three deliveries were less than 24 weeks of gestation. 
 
 
 
 
 
TABLE: 11
BIRTH WEIGHT IN 
Kg 
≤1.0
1.1 – 1.5
1.6 – 2.0
2.1 – 2.5
2.6 – 3.0
 
SEX: 
 As mentioned in review of literature, in this study also male sex 
preponderance is seen.Male baby 
This is shown in following figure: 
FIGURE: 5 NEONATAL
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 BIRTH WEIGHT 
NUMBER 
(n=107) 
PERCENTAGE
 9 8.41
 14 13.08
 38 35.51
 29 27.10
 17 15.88
– 72 (69%), female baby –
5. 
SEXES 
FEMALE (31%)
NEONATAL SEX
NEONATAL SEX35
 
% 
% 
% 
% 
% 
 35 (31%). 
 
PERINATAL MORBIDITY:
 There were 83 live births among 104 eclampsia patients.
wellbeing was assessed by Apgar score at 5min.
Apgar of ≥7 at five minutes.
41 NICU admissions among live births.
 Thirty Nine(39) 
for gestation babies were ad
including 3 twins. 16 babies had respiratory distress, which was settl
24 -48 hrs.11 had jaundice, required phototherapy.
during NICU admission due to hypoxia.2 had sepsis.6 neonatal deaths 
were recorded.Apgar score at 5 minutes is shown in figur
FIGURE: 6
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40 (49%) babies had 
11 (12%) babies had score of <3. 
 
of 83 live births were small for gestation. 
mitted in NICU.8 were preterm babies, 
6 neonates had seizures 
e: 6. 
 APGAR SCORE AT 5 MINUTES 
3 TO 7 (32) >7 (40)
APGAR SCORE
39%
49%
Neonatal 
There were 
16 small 
ed in 
 
APGAR SCORE
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Table: 12 show the perinatal morbidity in 80 live births. 
TABLE: 12 PERINATAL MORBIDITY 
PERINATAL MORBIDITY NUMBER (n=83) PERCENTAGE 
NICU admissions 41 49.39% 
Small for gestation 39 46.98% 
Preterm 8 9.63% 
Jaundice 11 13.25% 
Seizures 6 7.22% 
Respiratory distress 16 19.27% 
Sepsis 2 2.40% 
 
PERINATAL MORTALITY: 
 There were 431 perinatal deaths during the study period, 30 were 
due to eclampsia constituting 6.96%. There were 24 still births, of which 
12 were before admission and 9 after admission. 3 were macerated still 
birth.Six neonatal deaths were registered; all were less than 48 hrs.of 
admission in NICU. 
 Perinatal mortality rate to eclampsia was  3.56/1000 live 
births.Perinatal mortality was figured out in figure: 7. 
 
 
FIGURE: 7
 
SMALL FOR GESTATION:
 Thirty nine (39) of 107
As maternal age increases number of small babies were also 
increased.53% of babies born to mothers of age more than 25 were small 
for gestation.(P<0.05)
 Longer the duration of preeclampsia as marked by proteinuria more 
than 4 weeks increased babies with
proteinuria more than 4 weeks had small for gestation. 
PERINATAL MORTALITY (n=30)
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 babies (36.4%) were small for gestation.
 
 small for gestation. 62% patients with 
(P<0.01)
FSB BEFORE ADMISSION n=12
FSB AFTER ADMISSION n=9
MACERATED SB n=3
EARLY NEONATAL DEATH n=6
FSB - fresh still birth
40%
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 Earlier the onset of preeclampsia higher the rate of small for 
gestation. 30 patients among small for gestation group had onset of 
preeclampsia between 28-30 weeks of gestation.(P<0.01) 
 Maternal comorbid conditions like chronic hypertension, anemia, 
twin pregnancy were associated with increase in small for gestation 
babies. Out of 26 small for gestation 21 babies were IUGR. 
TABLE: 13 RISK FACTORS FOR SMALL FOR GESTATION IN 
ECLAMPSIA 
Risk factors 
Small for 
gestation 
(n=39) 
Appropriate for 
gestation 
(n = 68) 
P 
value 
Age > 25 
(n = 26 ) 
14 12 <0.05 
Onset of 
preeclampsia 
< 28 weeks 
(n = 29) 
19 10 <0.01 
Proteinuria > 4 
weeks 
(n = 57) 
35 22 <0.01 
Maternal 
comorbidity 
(n = 16) 
12 4 <0.01 
 
NUMBER OF SEIZURES AND PERINATAL OUTCOME: 
As number of seizures increased, it had impact on perinatal 
outcome.Total number of babies 107.63 patients had seizures less than 3. 
Of which 35 (54%) were well babies, 7 (11%) were stillbirth, 22 (33%) 
had NICU admissions.8 patients had seizures more than five episodes. 
Only 12% (1) was well baby, 50% (4) had NICU admissions, 38% (3) of 
 57 
 
babies were still birth.The impact of the repeated seizures on perinatal 
outcome is shown in table: 14. 
 
TABLE: 14NUMBER OF SEIZURES AND PERINATAL 
OUTCOME 
NO OF 
SEIZURES 
NO OF 
PATIENTS 
(n=104) 
WELL 
BABY 
(n=42) 
NICU 
ADMISSION 
(N=41) 
STILL 
BIRTH 
(n=24) 
< 3 63 
35 
(54%) 
22 (33%) 7 (11%) 
3 – 5 33 6 (16%) 15 (42%) 
14 
(42%) 
>5 8 1 (12%) 4 (50%) 3 (38%) 
 
 
FIGURE: 8 NUMBER OF SEIZURES AND PERINATAL 
OUTCOME 
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RISK FACTORS FOR PERINATAL MORTALITY: 
Twenty two of 78 women with age less than 25 years had perinatal 
mortality which includes 18 still births and 4 early neonatal deaths.10 of 
13 multipara women (79.92%) had 7 still births and 3 neonatal deaths. 
Nearly 50% of those women with either irregular ANC or unbooked had 
perinatal mortality.Gestational age at eclampsia also had impact. 15 
perinatal mortalities occured among 29 women with gestational age less 
than 32 weeks.These parameters has been put in table: 15. 
TABLE: 15 RISK FACTORS FOR PERINATAL MORTALITY 
Risk factors 
Total 
(n) 
Perinatal 
mortality(n=30) 
Percentage 
P 
value 
Age ≤ 25 78 22 28.20 % < 0.05 
Multiparity 13 10 79.92 % 
< 
0.001 
Irregular ANC/ 
Unbooked 
36 18 50.00 % < 0.01 
Gestational age 
≤ 32 weeks 
29 15 51.72 % < 0.01 
Seizures > 5 
episodes 
8 3 38% <0.05 
AP eclampsia 84 23 27.38% <0.05 
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MATERNAL COMPLICATIONS 
 Major complications of mothers with eclampsia were recorded. 
 Top on the list was postpartum hemorrhage (6), in spite of active 
management of third stage of labour. There were four (4) HELLP 
syndrome.Two (2) patients had renal failure, both required hemodialysis. 
Two patients had abruptio placenta. One (1) patient had aspiration during 
fits before admitting to hospital.One (1) had intracerebral hemorrhage, 
with admitting BP of  178/116 mm of Hg. Two patients had pulmonary 
edema. 
 Maternal complications are listed in table: 16 
TABLE: 16 MATERNAL COMPLICATIONS 
MATERNAL 
COMPLICATIONS 
NUMBER 
(n=18) 
PERCENTAGE 
(%) 
Post PartumHemmorhage 6 5.76 
HELLP syndrome 4 3.84 
Renal failure 2 1.92 
Abruptio placenta 2 1.92 
Aspiration 1 0.96 
Intracerebral hemorrhage 1 0.96 
Pulmonary edema 2 1.92 
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MARTERNAL MORTALITY: 
Total number of maternal deaths during the study period was 38. 
Maternal deaths due to eclampsia were four (4).10.5% of total maternal 
deaths were due to eclampsia.3.84% maternal mortality was seen in 104 
eclampsia patients during study period.25% was due to neurological 
cause and 50% was due to HELLP syndrome, 25% was due to pulmonary 
edema.Cause of maternal mortality is shown in table: 17. 
TABLE: 17 MATERNAL MORTALITY – CAUSES 
CAUSES NUMBER (n=4) PERCENTAGE 
HELLP syndrome-DIC 2 50% 
Intra cerebral hemorrhage 1 25% 
Pulmonary edema 1 25% 
 
RISK FACTORS ANALYSIS OF MATERNAL OUTCOME: 
Age less than 25 – among 26 eclampsia patients 16 were associated 
with maternal complications. This constituted 61.5% (p < 0.001) of total 
women less than 25 years. 
Primigravida as already proven, has strong correlation with 
eclampsia but only 12 of 91 primigravida had complications. This did not 
have statistical significance.  
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On the other hand multigravida had higher proportion of maternal 
complications. 6 out of 13 multigravida patients had maternal 
complications, contributing 46.15% with p value <0.01. 
Unbooked and patients with irregular antenatal checkup had more 
maternal complications.Recurrence of seizures ≥ 5 episodes had higher 
complications than with less than five episodes (33.33% Vs 15.21% 
p<0.01). 
Admission systolic blood pressure more than 160 mm Hg had 
significance in maternal complications. 13 among 35 patients with 
systolic blood pressure >160 mm Hg had complications, contributing 
37.14%. 
On the other side even with diastolic blood pressure of >110 mm 
Hg did not have significant impact on maternal complications. (4 of 20 
patients, 20.06%). 
Influence of various factors over maternal complications is enlisted 
in table: 18 
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TABLE: 18 RISKFACTORS FOR MATERNAL 
COMPLICATIONS 
RISKFACTORS 
MATERNAL 
COMPLICATIONS 
PERCENTAGE 
P 
VALUE 
Age > 25 (n=26) 16 61.5% <0.001 
Multipara (n=13) 6 46.15% <0.01 
Primipara (n=91) 12 13.18% NS
* 
Unbooked/ 
Irregular ANC 
(n=36) 
15 41.66% <0.01 
Recurrence of 
Seizure ≥5 (n=12) 
4 33.33% <0.01 
Systolic BP 
≥ 160 mm hg 
(n=35) 
13 37.14% <0.01 
Diastolic BP 
> 110 mm hg 
(n=20) 
4 20.06% NS
* 
*NS – NOT SIGNIFICANT 
 
 
 
 
 
FIGURE: 9 RISKFACTORS FOR MATERNAL 
PLATELET COUNT AND MATERNAL COMPLICATIONS
Platelet count had impact 
30 women with platelet count less than 1,00,000 had maternal 
complications. Constituting 46.66%, p value <0.01.Only 2 of 45 women 
with platelet count more than 1,50,000 had complications.
in table: 19. 
TABLE: 19  PLATELET AND MATERNAL COMPLICATIONS
PLATELET 
COUNT 
TOTAL
(n=104)
< 1,00,000 30 
1,00,000-
1,50,000 
29 
> 1,50,000 45 
0
5
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COMPLICATIONS 
on maternal outcome in eclampsia.14 of 
This is shown 
 
 
NO OF 
MATERNAL 
COMPLICATIONS 
(n=18) 
PERCENTAGE
(%) 
14 46.66% 
2 6.89% 
2 4.44% 
WITH COMPLICATION
WITHOUT COMPLICATION
 
: 
 
 P 
VALUE 
< 0.01 
< 0.01 
< 0.01 
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SERUM MAGENESIUM LEVEL AND MATERNAL 
COMPLICATIONS: 
Normal serum magnesium level as already mention is taken as              
1.8 – 3 mg/dl.Lower the magnesium level more the maternal 
complications.13 of 30 (43.33%) women with serum magnesium level 
1.00-1.59 mg/dl had complications, with p value less than 0.01. But only 
3 of 63 of women with serum magnesium level 1.60-2.09 mg/dl had 
complications.When magnesium level was 2.10 – 2.50 mg/dl two patients 
had renal failure hence elevated serum magnesium due to impaired 
excretion. The relation with serum magnesium level is shown in table: 20. 
 
TABLE: 20  SERUM MAGNESIUM AND MATERNAL 
COMPLICATIONS 
SERUM 
MAGNESIUM 
(mg/dl) 
TOTAL 
n=104 
MATERNAL 
COMPLICATIONS 
PERCENTAGE 
P 
VALUE  
WITH 
(n=18) 
 
WITHOUT 
(n=96) 
1.00 – 1.59 30 13 27 43.33% < 0.01 
1.60 – 2.09 63 3 60 4.76% < 0.01 
2.10 – 2.50 11 2 9 18.18% < 0.05 
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TYPE OF ECLAMPSIA –PERINATAL ANDMATERNAL 
OUTCOME: 
 Most common type was antepartum eclampsia, contributing 81% of 
total eclampsia patients. Among 24 still births 23 occurred in antepartum 
eclampsia and 1 in postpartum eclampsia (95.83% vs 4.16%). 34 of 41 
NICU admissions were due antepartum eclampsia compared to 3 and 4 
admissions in intrapartum and postpartum eclampsia respectively . But 
intrapartum eclampsia had higher proportion of NICU admissions than 
antepartum and postpartum eclampsia (50.00% vs 40.47% and 28.57%). 
82.92% of NICU admissions were from antepartum group.There were no 
maternal mortality or morbidity in intrapartum eclampsia group. All four 
maternal mortality were in antepartum eclampsia group.16 maternal 
complications in antepartum eclampsia and 2 in postpartum eclampsia 
group (19.04% vs 14.28%). 88.88% of maternal complications occurred 
in antepartum eclampsia.The above data is shown in following table: 21. 
TABLE: 21  TYPE OF ECLAMPSIA – PERINATAL AND 
MATERNAL OUTCOME 
 ANTEPARTUM 
INTRAPARTU
M 
POSTPARTUM 
Stillbirth(n=24) 23 95.83% NIL NIL 1 4.16% 
Nicu admissions(n=41) 34 82.92% 3 
7.31
% 
4 9.75% 
Maternal 
complications(n=18) 
16 88.88% NIL NIL 2 11.11% 
Maternal mortality(n=4) 4 100% NIL NIL NIL NIL 
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DISCUSSION 
Incidence of eclampsia: 
In our study over a period of 16 months 104 patients of eclampsia 
had been studied, with the incidence of 1.24%. Incidence in India varies 
between 0.5% and 1.8% 
66
.This incidence is similar to other African 
countries, 1.32%
67
. But still far behind the developed countries whose 
incidence is 8.4/10,000 deliveries
68
. 
Clinical profile: 
Eclampsia occurred in both extremes of age group in reproductive 
women. In our studyage group between 21 and 25 years constitute the 
maximum percentage of eclampsia(58%) similar to other studies
69
. 
The incidence of eclampsia is higher than figures from developed 
countries where there is better compliance with antenatal clinic 
attendances and easier access to specialist care, this is further 
demonstrated by the finding that only 65.38% of eclampsia patients had 
regular antenatal attendances in our study. 
The significant difference observed in the incidence of eclampsia 
amongst the very young and the primigravida (76%) compared to 
multigravida is in keeping with the findings of other studies
70
. 
Antepartum eclampsia accounted for the majority (81%) of the 
cases in our study. This was the finding in some earlier works
71
. But 
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study from UK showed relatively higher proportion of post partum 
eclampsia (44%)
72
 which was explained due to better antenatal care. 
The need for vigilance and close monitoring of patients in the 
immediate postpartum period especially those with features of 
preeclampsia is highlighted by the fact that 88% of first convulsions in 
postpartum period occurred within 12 hours of delivery
73
. 
Premonitory imminent symptoms were present in variable duration 
before seizures. 80 patients had imminent symptoms. Most common was 
headache, which was there in all patients who had imminent symptoms.   
Regarding gestational age maximum distribution was between 32 – 
37 weeks (57%), comparable to other studies
74
. 17% of women 
presented at term, ≥ 37 weeks. 
Overt Thrombocytopenia  (< 1 lakh) seen in 29% eclamptic women 
in our study            
Serum magnesium levels of eclamptic patients were significantly 
lower than normal value   (1.74 ± 0.28 mg/dl vs 1.8 – 3.0). 
Although the definitive management of eclampsia is delivery of the 
fetus and placenta as early as possible but as the eclampsia patient goes 
into labour quickly most of the patients delivered vaginally (57% vs 42% 
LSCS) consistent with other study from Pakistan
74
. Demographic picture 
is compared in table: 22 with study from Orrisa
75
 and Canada
76
. 
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TABLE: 22 DEMOGRAPHIC COMPARISION 
CHARACTERS 
OUR 
STUDY -
2011 
Singh S et al 
(ORRISA-2011) 
CANADIAN 
STUDY -2011 
Incidence 124/10000 320/10000 8.4/1000 
Unbooked 28.84% 97.4% - 
Age <25 69% 46% 30.5% 
AP eclampsia 81% 81.64% 70% 
Primiparity 76% 73% 54.96% 
 
Perinatal morbidity and mortality: 
Perinatal mortality in our study is 3.56/1000 total births.6.96% of 
perinatal deaths were due to eclampsia.This is comparable to studies 
from India (30 – 40 %) 
77 and neighbor countries like Nepal and 
Bangladesh
78
. 
Antepartum eclampsia was strongly associated with preterm 
eclampsia and hence is also associated with increased risk of perinatal 
complications and small for gestation.  
As the number of fits increased rate of NICU admission increased. 
50% NICU admissions and 38% mortality when number of seizures 
were more than 5. 
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Age ≤ 25 years, early onset preeclampsia, proteinuria more than 
four weeks duration and maternal comorbidity were significantly 
associated with small for gestation         (p <0.01). 
Perinatal mortality was significantly associated with multiparity 
(79.92% vs 20.08% p<0.001). 
Unbooked and patients with defaulting ANC care had 50% perinatal 
mortality (p<0.01). 
Gestational age less than 32 weeks had higher perinatal mortality 
(p<0.01). This is due an obvious reason of prematurity. 
Perinatal complications included NICU admissions, prematurity, birth 
asphyxia, seizures, respiratory distress, IUGR and sepsis. 
Late arrival of patients after onset of fits and recurrence result in 
severe intrauterine hypoxia and intrauterine death. Eclampsia occurring 
preterm necessitates preterm delivery. Available neonatal care facilities 
also determine the perinatal outcome. 
Basic characteristics and perinatal outcome is compared between 
Indian study from Karnataka
79
 and Canadian study
76
 in table: 23. 
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TABLE: 23PERINATAL OUTCOME COMPARISION 
 
OUR 
STUDY -
2011 
RAJSRI et al –
(KARNATAKA 
2011)
79 
CANADIAN 
STUDY – 
(2011)
76 
NICU 
admissions 
51.25% 47.88% 24.5% 
SGA* 37.5% - 20.6% 
Seizure 7.5% 10% 0.3% 
RDS
† 
20% 13% 0.7% 
Sepsis 2.5% 4% 0.24% 
Jaundice 13.5% 22% - 
Stillbirths 23% 20% 0.18% 
Preterm 10% 31% 17% 
Perinatal 
death 
3.56/1000 3.50/1000 - 
*SGA – small for gestation. 
†RDS – respiratory distress syndrome. 
 
Maternal outcome: 
In our study 17.30% (n=18) of eclampsia patients had 
complications. 
Eclampsia continues to be associated with significant maternal 
morbidity and mortality. 
Leading cause of maternal complications in our study was 
postpartum hemorrhage(33% of complications contributed by PPH) 
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similar to other study
74
. But in some studies pulmonary causes were 
leading morbidity,Renal failure, abruption, HELLP syndrome, rupture 
uterus, aspiration, intracerebral hemorrhage were the other causes of 
mortality.  
As in other studies patient who suffered intracranial hemorrhage 
did not survive. 
When age and parity increased the outcome of eclamptic mothers 
was bad. 
Thirty six (n=36) 41.6% of unbooked and patients with irregular 
ANC had complications. 
Twenty nine, n= 29 (28%) women had blood pressure more than or 
equal to 160/110 mmHg at admission. This group of patients developed 
most complications
80
. 
There were 4 maternal deaths during our study period. Constituting 
3.8% of case fatality rate and contributing to 10.5% of total maternal 
deaths during the same period in our institution. 
Maternal deaths were high among those who experienced 
antepartum eclampsia compared to those who had intrapartum or 
postpartum eclampsia. This could be partly explained by the relatively 
longer duration or possibly repeated episodes of convulsions from the 
onset of the first fit that often increases the mortality. 
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Maternal outcome is compared in table: 24. This is done with an 
Indian
75
 and Nigerian study
81
. 
TABLE: 24 COMPARISION OF MATERNAL OUTCOME. 
 
OUR 
STUDY -
2011 
Singh S et al 
(ORRISA-2011) 
NIGERIAN 
STUDY -2010 
Case fatality rate 3.8% 4.4% 8.5% 
Maternal 
mortality ratio 
8% 10.44% 12% 
Maternal 
complications 
17.3% 26.58% 30% 
Pulmonary 
edema 
25% 71% - 
Acute renal 
failure 
NIL 14.2% - 
Cerebral cause 25% 14.2% - 
Hellp-DIC 50% NIL - 
Last four rows indicate causes for maternal deaths. 
Platelet and serum magnesium in maternal outcome: 
Thrombocytopenia is associated with preeclampsia and eclampsia. 
As the platelet count dropped below 1 lakh (overt thrombocytopenia) the 
maternal complications increased. 46.66% had maternal complications 
compared to platelets more than 1,50,000 were only 2 of 45 patients had 
complications
81
. 
Serum magnesium is low during pregnancy but reduces further 
during preeclampsia
82
. In our study the serum magnesium level was 
significantly low1.74 ± 0.28 mg/dl (p<0.01). 
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 Furthermore low level of magnesium was found in patients with 
maternal complications than without complications (1.41 ±0.15 vs 1.84 ± 
0.16 p value <0.001).But 18.18%(n=11)patients(including 2 patients 
with renal failure) had magnesium values between 2.10 - 2.50mg/dl 
which may be due to renal dysfunction as explained by ShaliniM et al.,
83
. 
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CONCLUSION 
 
 To reduce the incidence andcomplications of eclampsia, there is 
dire need to improve antenatal care at community level.This 
includes booking of all antenatal mothers,identify the high risk 
mothers and ensureproper antenatal care with regular BP 
monitoring, which will result in early diagnosis of gestational 
hypertension. Health care providers and pregnant women with high 
BP should be sensitized for the imminent symptoms and early 
referral if it is present.  
 Multiparity is associated with adverse maternal and perinatal 
outcome hence it advisable to limit the family size. 
 Eclamptic patients should be given full loading dose before 
referring them to tertiary care to avoid recurrence of seizures and 
its hypoxic injury to both mother and fetus. 
 Vigilant postpartum care is required since postpartum eclampsia is 
common in first 12 hours of delivery and PPH is the most common 
maternal complication. 
 Early diagnosis and treatment of preeclampsia, appropriate 
measures to prevent recurrence of seizures and prompt referral to 
centre with newborn care facilities will reduce the perinatal 
mortality due to eclampsia. 
 Low platelet and low serum magnesium level were associated with 
adverse maternal outcome in eclamptic patients. Further studies are 
needed to validate the low serum magnesium level as predictor of 
maternal complications in eclampsia. 
S.No NAME AGE IP NUMBER ADRESS
PARITY 
INDEX
BOOKING STATUS LMP AGE PA AGE DIFF SYSTOLIC  BP
1 SATHYA 16 52572 gobi primi IRRU ANC 28 28 _ 180
2 RUBIDEVI 17 9518 MADUKARAI CBE primi REG ANC 36 36 _ 152
3 BINU 17 34897 CBE primi REG ANC 32 30 2WKS 160
4 SUGANTHY 18 69989 SALEM primi REG ANC 28 28 _ 140
5 RABIYA 18 69986 CBE primi REG ANC 36 36 _ 152
6 MOHANA 19 58016 AVINASHI primi IRRU ANC 34 28 6WKS 160
7 SANGEETHA 19 59011 SATHY primi REG ANC 36 32 4WKS 170
8 SUGANYA 19 71348 TIRUPUR primi REG ANC 30 26 4WKS 162
9 SUGANYA 19 71345 PALLADUM primi REG ANC 40 36 4WKS 160
10 PUSHPALATHA 19 70824 UDUMALAI G2A1 UB 34 34 _ 170
11 GEETHA 19 15147 gobi primi IRRU ANC 22 22 _ 154
12 poornima 20 9436 cbe primi REG ANC 38 34 4WKS 150
13 RANJITHA 20 30399 CBE primi REG ANC 37 32 5WKS 170
14 RABIYA 20 55317 CBE primi REG ANC 38 38 _ 150
15 ANDICHI 20 24000 UDUMALAI primi REG ANC 34 34 _ 114
16 SARATHY 20 6780 CBE primi REG ANC 36 32 4WKS 170
17 SUDHA 20 2724 METTUPALAYAM primi REG ANC 40 36 4WKS 140
18 SARASU 20 74565 CBE primi IRRU ANC 34 32 2WKS 172
19 DEVI 21 111545 SULUR CBE PRIMI REG ANC 38 38 _ 150
20 BAGAVATHY 21 24470 ANAIMALAI PRIMI REG ANC 32 32 _ 140
21 UMADEVI 21 39700 UDUMALAI primi REG ANC 36 32 4WKS 150
22 SARADHA 21 34918 SATHY primi IRRU ANC 36 30 6WKS 174
23 MEENA 21 11324 CBE primi REG ANC 36 36 _ 160
24 MUMTAJ 21 14332 ERODE primi IRRU ANC 32 28 4WKS 170
25 KAMATCHI 21 26544 ERODE primi UB 36 36 _ 174
26 JOTHIMANI 21 31241 CBE primi IRRU ANC 38 34 4WKS 190
27 JANAKI 21 32215 CBE primi REG ANC 34 34 _ 130
28 KRITHIGA 21 45413 CBE primi REG ANC 36 36 _ 160
29 ISWARYA 21 56732 CBE primi REG ANC 36 36 _ 162
30 mallika 22 9941 gobi primi IRRU ANC 36 30 6wks 140
31 GAYATHRI 22 9272 CBE PRIMI IRRU ANC 37 30 7WKS 150
32 VENI 22 24582 UDUMALAI G2P1L1 IRRU ANC 39 36 3WKS 152
33 SIVAGAMI 22 54780 SATHY primi IRRU ANC 28 28 _ 160
34 SUBULAKSHMI 22 64908 ERODE primi IRRU ANC 28 28 _ 148
35 JAYANTHI 22 2661 AVINASHI primi REG ANC 22 22 _ 150
S.No NAME AGE IP NUMBER ADRESS
PARITY 
INDEX
BOOKING STATUS LMP AGE PA AGE DIFF SYSTOLIC  BP
36 VANITHA 22 34545 CBE primi REG ANC 36 30 6wks 178
37 KALAI 22 67578 CBE primi REG ANC 36 32 4WKS 160
38 AMUTHA 22 34567 CBE primi REG ANC 36 36 _ 154
39 CHITRA 23 10987 CBE PRIMI REG ANC 38 36 2WKS 160
40 RANI 23 39763 POLLACHI primi REG ANC 36 36 _ 180
41 HEMAVATHY 23 36777 CBE G2P1L1 REG ANC 34 28 6WKS 124
42 DEVI 23 32425 CBE primi REG ANC 36 36 _ 160
43 KAMALEESHWARI 23 34528 KOTHAGIRI primi IRRU ANC 36 30 6WKS 162
44 RANGANAYAKI 23 34568 PEELAMEU CBE primi REG ANC 38 38 _ 130
45 JOTHI 23 11562 CBE primi REG ANC 36 36 _ 140
46 NAGAMANI 23 12358 CBE primi REG ANC 28 26 2WKS 178
47 VAITHESHWARI 23 21981 gobi primi REG ANC 38 38 _ 160
48 muthuselvi 23 26586 dharapuram primi UB 38 38 _ 170
49 GEETHA 23 3425 KOTHAGIRI primi IRRU ANC 32 26 6wks 178
50 PANDEESHWARI 23 62630 SULUR CBE primi REG ANC 36 34 2WKS 150
51 PANDISELVI 23 33422 CBE primi IRRU ANC 36 30 6WKS 178
52 CHITRA 23 56458 CBE primi REG ANC 36 36 _ 150
53 JAYALAKSHMI 23 34289 TIRUPUR G2P1L1 IRRU ANC 36 30 6wks 180
54 muthuselvi 23 676899 CBE primi REG ANC 36 36 _ 172
55 HEMAPRIYA 23 3556 CBE primi REG ANC 34 34 _ 140
56 MANI 23 54672 CBE primi REG ANC 34 34 _ 130
57 PRIYA 24 114435 OOTY G4P1L1A2 REG ANC 36 36 _ 142
58 NASERA 24 112323 UDUMALAI PRIMI REG ANC 38 38 _ 180
59 PREMA 24 52686 ERODE primi IRRU ANC 38 34 4WKS 150
60 SARASWATHY 24 43678 CBE G2A1 REG ANC 28 28 _ 152
61 SATHYA 24 61871 TIRUPUR primi REG ANC 28 28 _ 150
62 AMUTHA 24 60714 OOTY G2A1 IRRU ANC 36 30 6WKS 190
63 THERAISA 24 45644 METTUPALAYAM G2P1L1 IRRU ANC 36 36 _ 132
64 MEENA 24 21298 UDUMALAI primi REG ANC 32 32 _ 170
65 FARITHA BANU 24 31562 CBE primi REG ANC 36 36 _ 176
66 ANDICHI 24 65867 gobi primi REG ANC 32 32 _ 140
67 ARIFA 24 31657 TIRUPUR primi REG ANC 36 36 _ 170
68 VALLI 24 65432 CBE primi REG ANC 36 36 _ 148
69 MANIMEGALAI 24 55655 TIRUPUR primi IRRU ANC 34 28 6wks 160
70 CHINNU 24 43433 CBE G2A1 REG ANC 32 32 _ 150
S.No NAME AGE IP NUMBER ADRESS
PARITY 
INDEX
BOOKING STATUS LMP AGE PA AGE DIFF SYSTOLIC  BP
71 SELVI 25 71021 CBE G2A1 UB 22 22 _ 148
72 mallika 25 19887 POLLACHI primi REG ANC 36 30 6wks 160
73 KAVITHA 25 21307 TIRUPUR G2A1 IRRU ANC 28 26 2WKS 182
74 CHITRA DEVI 25 3979 TIRUPUR primi UB 36 32 4WKS 150
75 ESWARI 25 43531 TIRUPUR primi REG ANC 36 34 2WKS 140
76 DEVI 25 7895 ERODE primi REG ANC 36 32 4WKS 168
77 SEETHALAKSHMI 25 10453 OOTY primi IRRU ANC 34 26 8W 160
78 MEENA 25 43244 TIRUPUR primi REG ANC 36 36 _ 140
79 SIVAGAMI 26 60266 TIRUPUR primi REG ANC 28 28 _ 164
80 KATHAYEE 26 40622 CBE primi IRRU ANC 36 30 6wks 160
81 dhanalakshmi 26 65075 PERUR CBE G2A1 REG ANC 38 34 4WKS 140
82 SAJITHA 26 48289 CBE primi REG ANC 36 36 _ 158
83 VASANTHA 27 10161 TIRUPUR primi IRRU ANC 36 32 4WKS 170
84 CHITRA 27 23371 KUNIYAMUTHR CBE primi REG ANC 32 32 _ 162
85 SANUMA 27 37999 CBE primi REG ANC 34 32 2WKS 136
86 LATHAMANI 28 109877 SIRUMUGAI CBE G2P1L1 REG ANC 28 32 4WKS 150
87 MAHESHWARI 28 23029 CBE primi IRRU ANC 38 32 6WKS 170
88 SUMATHY 28 6173 AVINASHI G3P2L1 REG ANC 28 28 _ 172
89 KARTHIGA DEVI 28 5007 TIRUPUR primi UB 32 30 2WKS 160
90 RANJITHA 28 45432 CBE G2A1 REG ANC 36 32 4WKS 160
91 SACHU 28 32436 CBE primi REG ANC 34 34 _ 148
92 dhanalakshmi 29 11144 arulpuram cbe primi IRRU ANC 36 32 4WKS 150
93 RAMALAKSHMI 30 58257 VALPARAI G3P2L1 REG ANC 28 28 _ 200
94 SELVI 30 58023 TIRUPUR G3P1L1A1 UB 32 32 _ 156
95 KASTHURI 30 49289 ERODE G2P1L1 IRRU ANC 38 32 6wks 140
96 MYLAL 30 70144 ANNAMALAI primi UB 36 32 4WKS 164
97 ANANDHI 30 14745 TIRUPUR G2P1L1  TWIN REG ANC 34 34 _ 142
98 SELVI 30 30053 MADUKARAI CBE G2P1L0 REG ANC 34 34 _ 150
99 SARANYA 30 50032 MADUKARAI CBE primi REG ANC 34 34 _ 150
100 GOWRI 30 34345 CBE G3P1L1A1 REG ANC 32 30 2WKS 144
101 VENILLA 30 34564 CBE G4P1L1A2 REG ANC 34 30 4WKS 150
102 ESWARI 32 1940 CBE G3P2L2 REG ANC 36 36 _ 150
103 PREMA 35 34770 OOTY G10P9L8 UB 26 20 6wks 164
104 PARIMALA 38 71101 MADUKARAI CBE G5P3L3A1 REG ANC 28 28 _ 180
S.No NAME AGE IP NUMBER
diastolic  
BP
TYPE TIMES MODE WT IN KG PLAT MAGNESIUM LEVEL BABY
1 SATHYA 16 52572 132 AP 1 LSCS 1 87000 1.94 IUD
2 RUBIDEVI 17 9518 110 AP 4 LSCS 2.7 180000 1.53 NICU
3 BINU 17 34897 102 AP 3 VAGINAL 2.1 280000 2.1 NICU
4 SUGANTHY 18 69989 90  AP 1 VAGINAL 1.1 207000 2.3 NICU
5 RABIYA 18 69986 104 AP 1 LSCS 2.5 264000 2.5 WB
6 MOHANA 19 58016 100 PP 2+1 VAGINAL 2 120000 1.43 IUD
7 SANGEETHA 19 59011 102 PP 2 LSCS 2.2 290000 2.12 WB
8 SUGANYA 19 71348 100 AP 2 VAGINAL 1 200000 1.94 NICU
9 SUGANYA 19 71345 104 AP 1 LSCS 2.5 210000 1.89 WB
10 PUSHPALATHA 19 70824 110 AP 5 VAGINAL 1 74000 1.33 NICU
11 GEETHA 19 15147 100 AP 3 VAGINAL 0.6 250000 1.45 IUD
12 poornima 20 9436 100 AP 1 VAGINAL 2.1 30000 1.35 IUD
13 RANJITHA 20 30399 112 AP 3 VAGINAL 3 180000 1.92 NICU
14 RABIYA 20 55317 110 AP 7 LSCS 2.5 300000 1.35 WB
15 ANDICHI 20 24000 72 AP 3 LSCS 1.75 180000 1.36 NICU
16 SARATHY 20 6780 110 AP 3 LSCS 1.9 100000 2.34 NICU
17 SUDHA 20 2724 114 AP 1 VAGINAL 2 230000 2.19 NICU
18 SARASU 20 74565 110 AP 3 VAGINAL 2 100000 1.33 NICU
19 DEVI 21 111545 110 AP 2 LSCS 2.6 200000 1.67 WB
20 BAGAVATHY 21 24470 112 AP 4 LSCS 2.1 110000 1.89 IUD
21 UMADEVI 21 39700 100 AP 4 VAGINAL 2 100000 1.88 IUD
22 SARADHA 21 34918 110 AP 3 VAGINAL 1.3 140000 1.93 WB
23 MEENA 21 11324 110 PP 2 LSCS 2.3 120000 1.99 WB
24 MUMTAJ 21 14332 106 AP 3 VAGINAL 1.4 40000 1.4 IUD
25 KAMATCHI 21 26544 110 PP 1 LSCS 2.5 122000 1.25 WB
26 JOTHIMANI 21 31241 90 AP 2 VAGINAL 2 111000 2.33 WB
27 JANAKI 21 32215 90 AP 2 VAGINAL 2 120000 1.98 NICU
28 KRITHIGA 21 45413 102 PP 1 VAGINAL 2.8 200000 2.13 WB
29 ISWARYA 21 56732 114 AP 1 VAGINAL 2.7 340000 1.89 WB
30 mallika 22 9941 110 AP 5 VAGINAL 1.9 150000 1.46 WB
31 GAYATHRI 22 9272 116 AP 1 VAGINAL 1.8 120000 2.34 WB
32 VENI 22 24582 100 AP 2 LSCS 2.3 120000 1.76 NICU
33 SIVAGAMI 22 54780 136 AP 2 VAGINAL 1.3 290000 1.66 NICU
34 SUBULAKSHMI 22 64908 90 IP 2 VAGINAL 1.5 100000 2.45 WB
35 JAYANTHI 22 2661 100 AP 3 VAGINAL 0.5 42,000 1.96 IUD
S.No NAME AGE IP NUMBER
diastolic  
BP
TYPE TIMES MODE WT IN KG PLAT MAGNESIUM LEVEL BABY
36 VANITHA 22 34545 110 AP 4 LSCS 2 110000 1.88 NICU
37 KALAI 22 67578 110 AP 2 VAGINAL 2.3 240000 1.76 WB
38 AMUTHA 22 34567 112 AP 2 VAGINAL 2.4 130000 1.98 WB
39 CHITRA 23 10987 100 PP 1 VAGINAL 2.1 110000 1.67 WB
40 RANI 23 39763 108 AP 3 LSCS 1.7 100000 1.45 IUD
41 HEMAVATHY 23 36777 92 AP 1 LSCS 1.80 100000 1.33 IUD
42 DEVI 23 32425 120 AP 2 LSCS 2.4 230000 1.81 WB
43 KAMALEESHWARI 23 34528 110 AP 12 LSCS 1.4 80000 1.23 IUD
44 RANGANAYAKI 23 34568 84 AP 4 LSCS 2.8 240000 1.91 WB
45 JOTHI 23 11562 100 IP 1 OUTLET 3 200000 1.95 WB
46 NAGAMANI 23 12358 116 AP 5 VAGINAL 0.6 55000 1.35 IUD
47 VAITHESHWARI 23 21981 110 AP 3 LSCS 2.7 65000 1.84 WB
48 muthuselvi 23 26586 102 PP 5+1 LSCS 3 154000 1.32 NICU
49 GEETHA 23 3425 120 AP 5 VAGINAL 0.7 374000 1.56 IUD
50 PANDEESHWARI 23 62630 110 PP 2 VAGINAL 2 230000 1.82 WB
51 PANDISELVI 23 33422 100 AP 2 VAGINAL 2 120000 1.87 NICU
52 CHITRA 23 56458 100 PP 1 VAGINAL 2.6 250000 1.86 WB
53 JAYALAKSHMI 23 34289 110 IP 4+1 LSCS 2.1 88,000 1.89 NICU
54 muthuselvi 23 676899 106 AP 1 LSCS 2.4 200000 1.92 WB
55 HEMAPRIYA 23 3556 110 AP 1 LSCS 2.4 120000 1.94 WB
56 MANI 23 54672 90 AP 1 VAGINAL 2.3 270000 1.96 WB
57 PRIYA 24 114435 110 AP 1 VAGINAL 2.3 100000 1.74 WB
58 NASERA 24 112323 106 AP 2 LSCS 2.7 180000 1.72 WB
59 PREMA 24 52686 110 AP 4 LSCS 1.5 100000 1.35 IUD
60 SARASWATHY 24 43678 110 AP 2 VAGINAL 1 200000 1.67 NICU
61 SATHYA 24 61871 102 AP 2 LSCS 1.3 140000 1.79 NICU
62 AMUTHA 24 60714 110 AP 2 VAGINAL 2 145000 1.76 NICU
63 THERAISA 24 45644 80 AP 1 LSCS 2.5 100000 1.49 IUD
64 MEENA 24 21298 116 AP 1 VAGINAL 1.6 140000 1.78 NICU
65 FARITHA BANU 24 31562 100 AP 2 VAGINAL 2.6 123000 1.82 WB
66 ANDICHI 24 65867 100 AP 2 VAGINAL 2 260000 1.85 NICU
67 ARIFA 24 31657 100 AP 2 LSCS 2.6 123000 1.84 WB
68 VALLI 24 65432 110 PP 2 VAGINAL 2.6 260000 1.86 WB
69 MANIMEGALAI 24 55655 100 AP 3 LSCS 1.8 170000 1.64 NICU
70 CHINNU 24 43433 110 AP 2 LSCS 2.3 180000 1.71 NICU
S.No NAME AGE IP NUMBER
diastolic  
BP
TYPE TIMES MODE WT IN KG PLAT MAGNESIUM LEVEL BABY
71 SELVI 25 71021 106 AP 5 VAGINAL 0.8 100000 1.21 IUD
72 mallika 25 19887 110 AP 3 VAGINAL 1.5 150000 1.73 WB
73 KAVITHA 25 21307 110 AP 2 VAGINAL 1.2 112000 1.75 IUD
74 CHITRA DEVI 25 3979 100 AP 4 VAGINAL 2 200000 1.71 NICU
75 ESWARI 25 43531 102 AP 2 VAGINAL 2.1 180000 1.77 NICU
76 DEVI 25 7895 110 AP 4 VAGINAL 2 200000 1.79 NICU
77 SEETHALAKSHMI 25 10453 116 AP 4 VAGINAL 1 180000 1.61 IUD
78 MEENA 25 43244 110 PP 1 VAGINAL 2.5 150000 1.63 WB
79 SIVAGAMI 26 60266 112 AP 2 VAGINAL 1.75 280000 1.65 NICU
80 KATHAYEE 26 40622 100 AP 1 LSCS 1.8 100000 1.67 IUD
81 dhanalakshmi 26 65075 104 AP 2 LSCS 2 94000 1.69 WB
82 SAJITHA 26 48289 100 AP 2 VAGINAL 2.6 280000 1.77 WB
83 VASANTHA 27 10161 112 AP 5 LSCS 1.8 120000 1.49 IUD
84 CHITRA 27 23371 104 AP 1 LSCS 1.7 55000 1.36 NICU
85 SANUMA 27 37999 100 AP 1 VAGINAL 2.3 130000 2.32 WB
86 LATHAMANI 28 109877 106 PP 4+6 LSCS 1.7 180000 1.47 NICU
87 MAHESHWARI 28 23029 112 AP 4 VAGINAL 1.2 59000 1.5 IUD
88 SUMATHY 28 6173 100 AP 3 LSCS 0.7/0.8 122000 1.85 IUD
89 KARTHIGA DEVI 28 5007 104 PP 4+1 LSCS 1.9/2 92000 1.43 NICU
90 RANJITHA 28 45432 100 AP 1 VAGINAL 2.4 120000 2.01 NICU
91 SACHU 28 32436 106 AP 1 LSCS 2.6 180000 1.67 WB
92 dhanalakshmi 29 11144 102 AP 2 LSCS 2 100000 1.97 NICU
93 RAMALAKSHMI 30 58257 120 AP 3 VAGINAL 2.2 280000 1.83 NICU
94 SELVI 30 58023 110 AP 2 LSCS 2 120000 1.33 NICU
95 KASTHURI 30 49289 110 AP 2 LSCS 2.5 150000 1.38 WB
96 MYLAL 30 70144 100 PP 1+1 VAGINAL 1 90000 1.6 NICU
97 ANANDHI 30 14745 100 IP 2+1 VAGINAL 1.8 200000 1.57 NICU
98 SELVI 30 30053 116 IP 2 LSCS 2 98000 1.65 NICU
99 SARANYA 30 50032 100 IP 2 VAGINAL 2.2 280000 2.03 WB
100 GOWRI 30 34345 100 AP 1 VAGINAL 2.3 280000 1.65 WB
101 VENILLA 30 34564 112 AP 2 LSCS 2 100000 1.98 NICU
102 ESWARI 32 1940 110 AP 3 VAGINAL 1.75 270000 1.87 NICU
103 PREMA 35 34770 120 AP 1 VAGINAL 0.7 95000 1.37 IUD
104 PARIMALA 38 71101 100 AP 3 VAGINAL 1 100000 1.33 IUD
S.No NAME AGE IP NUMBER NEONATAL COMP MATERNAL COMP SEX IMM SIGNS AN DIAGN
1 SATHYA 16 52572 RENAL FAILURE F H1WK BP +
2 RUBIDEVI 17 9518 TWINS M/F _ BP(-)
3 BINU 17 34897 M H BP(-)
4 SUGANTHY 18 69989 M H BP(-)
5 RABIYA 18 69986 M H,V BP(-)
6 MOHANA 19 58016 M H BP +
7 SANGEETHA 19 59011 SGA RENAL FAILURE M H BP(-)
8 SUGANYA 19 71348 PRETERM M H BP(-)
9 SUGANYA 19 71345 SGA M H BP(-)
10 PUSHPALATHA 19 70824 SEIZURES PPH M H BP +
11 GEETHA 19 15147 CHT M H BP +
12 poornima 20 9436 HELLP,MM M _ BP +
13 RANJITHA 20 30399 SGA M _ BP(-)
14 RABIYA 20 55317 M _ BP(-)
15 ANDICHI 20 24000 PPH M H BP(-)
16 SARATHY 20 6780 SGA M H,V BP(-)
17 SUDHA 20 2724 SGA M H,V BP(-)
18 SARASU 20 74565 sepsis PPH M H BP(-)
19 DEVI 21 111545 F _ BP +
20 BAGAVATHY 21 24470 M _ BP(-)
21 UMADEVI 21 39700 M H(+) BP(-)
22 SARADHA 21 34918 SGA M _ BP +
23 MEENA 21 11324 F H BP(-)
24 MUMTAJ 21 14332 HELLP,MM M H BP +
25 KAMATCHI 21 26544  ABRUPTION M H BP +
26 JOTHIMANI 21 31241 SGA M H,V BP(-)
27 JANAKI 21 32215 M H,V BP(-)
28 KRITHIGA 21 45413 M _ BP +
29 ISWARYA 21 56732 M H,V BP +
30 mallika 22 9941 SGA M _ BP(-)
31 GAYATHRI 22 9272 SGA F _ BP +
32 VENI 22 24582 LBW M _ BP(-)
33 SIVAGAMI 22 54780 preterm DIED -1DAY M H10D BP +
34 SUBULAKSHMI 22 64908 M H BP +
35 JAYANTHI 22 2661 PPH M H BP +
S.No NAME AGE IP NUMBER NEONATAL COMP MATERNAL COMP SEX IMM SIGNS AN DIAGN
36 VANITHA 22 34545 SGA M H,V BP +
37 KALAI 22 67578 SGA M H BP +
38 AMUTHA 22 34567 F H BP(-)
39 CHITRA 23 10987 M _ BP +
40 RANI 23 39763 M H-12 BP(-)
41 HEMAVATHY 23 36777 PULMONARY EDEMA MM F _ BP(-)
42 DEVI 23 32425 F H,V,BV BP +
43 KAMALEESHWARI 23 34528 M H BP +
44 RANGANAYAKI 23 34568 M H BP(-)
45 JOTHI 23 11562 F H BP(-)
46 NAGAMANI 23 12358 ICH,MM M H BP(-)
47 VAITHESHWARI 23 21981 M H BP(-)
48 muthuselvi 23 26586 PULMONARY EDEMA M H,V,BV BP +
49 GEETHA 23 3425 M H,V BP +
50 PANDEESHWARI 23 62630 M H BP +
51 PANDISELVI 23 33422 SEIZURES M H BP(-)
52 CHITRA 23 56458 M H BP +
53 JAYALAKSHMI 23 34289 DIED -1DAY F H,V,BV BP +
54 muthuselvi 23 676899 M H BP(-)
55 HEMAPRIYA 23 3556 M H BP +
56 MANI 23 54672 F H BP(-)
57 PRIYA 24 114435 M _ BP(-)
58 NASERA 24 112323 M _ BP +
59 PREMA 24 52686  ABRUPTION F H BP +
60 SARASWATHY 24 43678 DIED -1DAY F H BP(-)
61 SATHYA 24 61871  preterm,DIED -1DAY M H,V,BV BP(-)
62 AMUTHA 24 60714 SGA F H BP +
63 THERAISA 24 45644 MACERATED ASPIRATION M _ BP(-)
64 MEENA 24 21298 M H BP(-)
65 FARITHA BANU 24 31562 F H,V BP +
66 ANDICHI 24 65867 SEIZURES M H BP(-)
67 ARIFA 24 31657 F H,V BP +
68 VALLI 24 65432 M H BP +
69 MANIMEGALAI 24 55655 SEIZURES F H,V BP +
70 CHINNU 24 43433 PRETERM F H BP +
S.No NAME AGE IP NUMBER NEONATAL COMP MATERNAL COMP SEX IMM SIGNS AN DIAGN
71 SELVI 25 71021 M H BP(-)
72 mallika 25 19887 SGA M H2D BP(-)
73 KAVITHA 25 21307 F H BP(-)
74 CHITRA DEVI 25 3979 SEIZURES M H BP(-)
75 ESWARI 25 43531 sepsis F _ BP +
76 DEVI 25 7895 SGA M H BP +
77 SEETHALAKSHMI 25 10453 F H,V BP +
78 MEENA 25 43244 F H BP +
79 SIVAGAMI 26 60266 PRETERM M H,V BP(-)
80 KATHAYEE 26 40622 F H BP(-)
81 dhanalakshmi 26 65075 SGA M H BP(-)
82 SAJITHA 26 48289 M H BP(-)
83 VASANTHA 27 10161 M _ BP(-)
84 CHITRA 27 23371 SEIZURES HELLP F _ BP +
85 SANUMA 27 37999 M H BP(-)
86 LATHAMANI 28 109877 PRETERM M _ BP(-)
87 MAHESHWARI 28 23029 PPH F _ BP +
88 SUMATHY 28 6173 TWINS F/F H,V,BV BP +
89 KARTHIGA DEVI 28 5007 TWINS M/F H,V,BV BP +
90 RANJITHA 28 45432 SGA M H BP(-)
91 SACHU 28 32436 F H BP(-)
92 dhanalakshmi 29 11144 SGA M _ BP +
93 RAMALAKSHMI 30 58257 PRETERM M H,V,BV BP +
94 SELVI 30 58023 PRETERM M H BP(-)
95 KASTHURI 30 49289 HELLP F H BP(-)
96 MYLAL 30 70144 DIED -1DAY PPH F H2D BP(-)
97 ANANDHI 30 14745 M _ BP +
98 SELVI 30 30053 DIED -1DAY F H,V BP +
99 SARANYA 30 50032 F H BP +
100 GOWRI 30 34345 F H BP +
101 VENILLA 30 34564 SGA M H,V BP +
102 ESWARI 32 1940 F H BP(-)
103 PREMA 35 34770 CHT M _ BP +
104 PARIMALA 38 71101 M H BP +
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PROFORMA 
 
ANALYSIS OF FETOMATERNAL OUTCOME IN 
ECLAMPSIA 
 
NAME   AGE  IP NO:  
ADRESS: 
BOOKING STATUS:   PARITY:  
 GESTATIONAL AGE: 
TYPE OF ECLAMPSIA: AP/IP/PP NUMBER OF FITS: 
ADMISSION BP:   TIME SINCE FITS: <6HRS / >6HRS 
ANTENATAL DIAGNOSIS OF PREECLAMPSIA: YES/NO. 
INDUCTION: YES/NO.   MODE OF DELIVERY: 
 SEX: 
APGAR AT 5MIN:   LIVE/STILLBIRTH: 
 BIRTH WEIGHT: 
NICU ADMISSION: YES/NO. 
PERINATAL COMPLICATIONS: 
MATERNAL COMPLICATIONS:  
IF MATERNAL DEATH – CAUSE: 
  
 
ABBREVIATIONS 
AP – antepartum   
BP – blood pressure 
CHT – chronic hypertension 
DIC – disseminated intravascular coagulation 
FBS – fresh still birth 
ICH – intra cerebral hemorrhage 
IP – intrapartum  
IUGR – intra uterine growth restriction 
LSCS – lower segment caesarian section 
MgSo4 – magnesium sulphate 
MM – maternal mortality 
PIH – pregnancy induced hypertension 
PP – postpartum  
PPH – post partum hemorrhage 
SGA – small for gestation 
WB – well baby 
